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Drug delivery systems with targeted or site-specific property and high efficacy 
hold great promise for treatment of various cancers. To achieve such 
advancement, nanotechnology has been exploited to develop soft 
nanoparticles (NPs) with tailorable functionalities. In this study, different 
types of soft NPs were investigated as drug carriers for potential applications 
in intravesical drug delivery (IDD) or intravenous targeted delivery. A 
polyacrylamide nanogel (PAm-NH2) was first evaluated for sustained delivery 
of a hydrophobic drug to bladder cancers. Secondly, chitosan-polymethacrylic 
acid (CM) nanocapsules were designed for combined loading of doxorubicin 
(Dox) and peptide-modified cisplatin (Pt-ALy). The dual-drug loaded 
nanocapsules (CM-Dox-PtALy) demonstrated obvious synergistic effects 
against UMUC3 bladder cancer cells with combination index (CI) much lower 
than 1 at different fractions of affected cells. For IDD, an ex vivo model based 
on porcine bladder was used for evaluating mucoadhesiveness. Both above-
mentioned systems are mucoadhesive and showed great potential for site-
specific chemotherapy in the bladder. Finally, for potential intravenous 
application, polyacrylamide/gold (Au-PAm-NH2) hybrid nanogels were 
prepared and covalently conjugated with methotrexate (MTX) for targeted co-
delivery to ovarian cancer. These hybrid nanogels (Au-PAm-MTX) at a 
dosage of 0.5 mg/ml or higher exhibit enhanced killing efficacy and 
suppressed recovery of KB cancer cells compared to either cytotoxic Au NPs 
or MTX loaded in nanogels. On the other hand, these MTX-functionalized 
 vii 
 
hybrid nanogels are well-tolerated by macrophages, indicating that such 
delivery systems are not likely to initiate immune responses in the 
physiological environment and their circulation life time will be prolonged.  
 viii 
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DLS Dynamic light scattering  
DMEM Dulbecco’s Modified Eagle’s Medium  
DMSO Dimethyl sulfoxide  
Dox Doxorubicin 
Dox·HCl Doxorubicin hydrochloride  
DRI Dose-reduction index  
DTX Docetaxel 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide  
EGFR Epidermal growth factor receptor  
EPR Enhanced permeability and retention 
ESI-MS Electrospray ionization mass  
FA Folic acid  
Fa Affected cells  
FBS Fetal bovine serum 
FESEM Field emission scanning electron microscope 




FR Folate receptor 
GA Glutaraldehyde 
GAG Glycosaminoglycan 
GDA Glycerol dimethacrylate  
HAc Acetic acid  
HTS High throughput screen 
IC50 Half-maximal inhibitory concentrations 
ICP-MS Inductively coupled plasma mass spectrometer 
IDD Intravesical drug delivery 
LHRH Luteinizing hormone-releasing hormone  
MAA Methacrylic acid  
MPS Mononuclear phagocytic system  




MWCO Molecular weight cutoff  
NHS N-hydroxysuccinimide  








PEG Polyethylene glycol  
PLA Poly(lactic acid) 
PMAA Poly(methacrylic acid)  
PTA Phosphotungstic acid 
Pt-ALy Nα-acetyllysine-modified CDDP  
PTX Paclitaxel  
QDs Quantum dots  
RES Reticuloendothelial system  
SEM Scanning electron microscopy  
SPR Surface plasmon resonance 
TCC Transitional cell carcinomas  
TEA Triethanolamine 
TEM Transmission electron microscopy 
TEMED Tetramethylethylenediamine 
TI Therapeutic index 
TUR Transurethral resection 
W/O Water/oil  
















Cancer is a form of tissue malignancy caused by genetic instability and 
accumulation of multiple molecular alterations, leading to uncontrolled tumor 
proliferation. In 2014, approximately 1600 people will die from cancer each 
day in the United States of America (American Cancer Society, 2014). While 
the rate of cancers being diagnosed has gradually increased, the cancer-related 
death rate for all cancers diagnosed has remained virtually unchanged 
(American Cancer Society, 2015). The current prognostic classifications for 
cancer are insufficient to reflect the whole clinical heterogeneity of tumors and 
often fail to predict patient outcome. Due to lack of effective treatment, cancer 
often recurs among patients after surgical removal of tumor. In Singapore, the 
cancer death rate is 29.3% in 2009, highest among all other diseases. 
Chemotherapy is among the most commonly used treatment modality for 
controlling and inhibiting tumor development. Drug delivery system (DDS) 
via integration of therapeutic agents into nano-sized formulations (also called 
nanomedicine) is now a promising mode of chemotherapy. Currently, 
chemotherapeutic formulations can be administrated by methods such as 
intravenous injection, intra-tumoral injection and intravesical instillation. 
However, in each mode of administration, DDSs face some shortcomings. In 
intravenous application, injection-based systems usually suffer from low 
circulation time due to systemic elimination. In addition, most DDSs are not 
able to effectively differentiate between cancerous and normal cells, leading to 




are limited in their effectiveness on patients. On the other hand, intravesically 
delivered drugs are typically able to bypass systemic elimination but have 
issues with low residence time and poor drug permeability due to the special 
structure in the bladder. It was also reported that intravesical delivery often 
cause painful therapy or disruption of the bladder urothelium due to the 
solvent or materials used (Tyagi et al., 2006). 
The advancement of nanotechnology and its bio-related application in the past 
decades provide broad prospects in meliorating the state of art of cancer 
treatment. Nanocarrier-assisted drug formulations, so-called "nanomedicine", 
provide a practical strategy for DDS with various routes of administration. 
Currently, three main challenging problems for these nanomedicine 
formulations remain: their uncertain stability in physiological environment, 
their low accumulation in tumor, and their adverse side effects on normal 
organs. Engineered soft nanoparticles (NPs) have recently garnered much 
attention in the development of advanced DDSs (Soussan et al., 2009). This is 
primarily because soft NPs can potentially be used for constructing a variety 
of structures (as reviewed in Chapter 2) with the desired properties for 
effective, specific and safe delivery of chemotherapeutic drugs to tumors. 
With different types of starting materials, including synthetic polymers and 
biopolymers which impart biocompatibility, biodegradability and anti-
immunogenicity, soft NPs are versatile. 
 




The overall aim of this thesis is to develop different soft nanomaterials to fulfil 
the requirements of DDSs for potential cancer chemotherapy via two methods 
of administration: intravesical and intravenous applications. For intravesical 
therapy, a hydrophilic nanocarrier with mucoadhesive property was tailored to 
incorporate an effective hydrophobic drug in its matrix (to facilitate its 
intravesical instillation) and a hollow-structured nanocarrier for high co-
loading of hydrophilic and hydrophobic drugs with strong synergistic effects 
against bladder cancers was developed. The hydrophilic nanocarrier was 
subsequently exploited for integrating two potential therapeutic compounds 
for intravenous injection where cancer targeting, macrophage-evasion and 
drug release without the initial burst effect have to be considered.  
This thesis comprises six chapters. In Chapter 1, the problems faced by DDS 
for cancer chemotherapy are introduced, and the objectives and scope of this 
study are laid out. Chapter 2 provides an overview of the literature relevant to 
this study. Chapter 3 describes the development of a degradable and amine-
functionalized polyacrylamide nanogel (PAm-NH2) as a carrier to increase the 
solubility of hydrophobic drugs (using docetaxel (DTX) as a model), which 
are hard to instil intravesically into the bladder. Sustained release of DTX 
from the hydrophilic nanogel-matrix and cellular internalization process of the 
nanogel are thoroughly investigated. Chapter 4 is on the development of 
hollow-structured chitosan-polymethacrylic acid (CM) nanocapsules for 
combined loading of two therapeutical drugs with high loading capacity. Since 




(IDD), cisplatin was modified with an amine-terminated peptide and 
effectively co-loaded into CM nanocapsules together with doxorubicin (Dox) 
for enhanced anticancer effects. The synergistic effects of the dual-drug 
loaded nanocapsule against UMUC3 bladder cancer cells were evaluated in 
vitro. Chapter 5 describes the construction of targeting hybrid nanogels for 
potential intravenous application. Small-sized gold nanoparticles (NPs) were 
loaded into the PAm-NH2 nanogels, and methotrexate (MTX) was covalently 
conjugated to the hybrid nanogels in order to circumvent burst drug release, a 
common phenomenon in DDS. MTX, an analogue of folic acid (FA), was not 
only used as a chemotherapeutic agent, but also as a targeting ligand for folate 
receptor (FR)-positive ovarian cancer cell, KB. Co-delivery of the Au NPs and 
MTX via the hybrid nanogels for effective killing of the targeted KB cells, 
inhibition of cancer cell recovery and evasion of non-targeted immune cells 
(macrophages) was investigated. Finally, the major conclusions of the work 














2.1 Engineered Soft Nanoparticles 
Soft materials are primarily organic and amorphous materials that can be 
easily deformed under an external stimulus (like certain stresses or thermal 
fluctuations) (Nayak and Lyon, 2005, Steed and Gale, 2012). They exist in our 
daily life in various forms – such as gels, colloids, foams, rubbers, liquids, and 
plastics (Steed and Gale, 2012). Besides synthetic polymers, soft materials are 
also found in biological fluids such as blood and milk, and biological 
substructures such as cells and connective tissues. Unlike “hard” materials, 
such as metals, semiconductors, nanotubes, etc., soft materials have tailorable 
macroscopic properties (Nayak and Lyon, 2005). The behaviours of soft 
systems vary across a range of length scales. As such, tuning their properties 
can be achieved by changing structures ranging from molecular scale, 
nanoscale/microscale, to mesoscopic level. Due to this excellent tailorable 
property, soft materials have been widely used in cosmetics, packaging, 
modern diet, fuel cells, water filtration and desalination, liquid crystal displays, 
automobiles, aerospace, and other structural applications. These materials are 
also exploited in the fields of tissue engineering and advanced pharmaceutical 
therapies.  
Advances in the field of nanotechnology have led to new designs of soft 
materials with precise nanostructure for a wide range of applications (Boey et 
al., 2011). Soft nanomedicine is deemed as one of the most promising 
therapeutics in anti-cancer therapy (Soussan et al., 2009). New classes of soft 




with rapid growth of chemical synthesis routes (John and Vemula, 2006, 
Nayak and Lyon, 2005). Examples of recently formulated products are 
polymer micelles, nanogels, nanocapsules (including liposomes), dendrimers 
and biopolymer-based nanocarriers (Figure 2.1). 
 
Figure 2.1. Schematic structure of different nanocarriers (micelle and nanogel, 
nanocapsule (liposome), dendrimer, biopolymer-based nanocarriers) 
[reproduced with permission from (Matsumoto et al., 2013, Orive et al., 
2009)]. 
 
2.1.1  Micelles 
Polymeric micelles are formulated from lipids or synthetic biodegradable 




with core-shell structure, through an entropy-driven process (Yokoyama et al., 
1990). Micelles have the advantage of being small in size, uniformity, and 
ease of incorporating different components. The size of the micelles can range 
from a few to tens of nanometers and they comprise a dense hydrophobic 
region in the core and a dense hydrophilic corona. Polymeric micelles are 
well-known for their ability to encapsulate hydrophobic drugs in their cores, 
protecting the drugs from metabolic degradation and hence allowing them to 
be transported to the tumors (Cho et al., 2015). Introducing functional units 
(like -NH2, -COOH, or -SH groups) on the micellar shell offer opportunities 
for conjugation of targeting ligands for active targeting to tumors (Zhang et al., 
2014). 
The hydrophilic shell with brush-like structure is able to stabilize the 
hydrophobic core in an aqueous environment and prevent the micelles from 
biological milieu. Polyethylene glycol (PEG)-based polymers are widely used 
as a hydrophilic and neutral shell for micelles due to their excellent 
biocompatibility and low cost. It can minimize protein adsorption and hence 
reduce recognition by the immune system in the body (Kwon and Forrest, 
2006). Such structure thus not only prolongs the circulation time of carriers in 
the body but also enhances their accumulation at the target site due to passive 
targeting (Ahmad et al., 2014, Kwon and Forrest, 2006). Slightly negatively 
charged shell of micelles can also significantly reduce nonspecific uptake by 
liver and spleen, resulting in minimal blood clearance (Xiao et al., 2011, 




charged micelles have been demonstrated to suffer from highly undesirable 
liver uptake, which is likely due to active phagocytosis by macrophages (Xiao 
et al., 2011). Therefore, highly charged micelles are not desired for in vivo 
application although surface charges introduced onto the shell can improve the 
micellar stability (Tian and Mao, 2012). The micellar core is well suited for 
incorporating poorly-soluble or hydrophobic drug molecules by physical 
entrapment (Kwon et al., 1997). Hydrophobic and ionic interactions have also 
been used to facilitate physical drug entrapment. A large number of high 
throughput screen (HTS)-derived hits, lead molecules, development 
candidates and eventually, marketed drugs share the common characteristics 
of high hydrophobicity and consequently, low aqueous solubility (Williams et 
al., 2013). Currently, around 40% of commercial drugs and >75% of 
compounds under development are poorly water-soluble (Di et al., 2012, Di et 
al., 2009). Anti-cancer drugs are most often polycyclic compounds and are 
likely to be highly hydrophobic. Parenteral administration of hydrophobic 
drugs is problematic since drug aggregates may cause embolization of blood 
and promote metabolic degradation which results in the decrease in bioactivity 
of drugs (Fernandez et al., 2001). All these factors thus result in low systemic 
drug concentration and short circulation fate in blood (Torchilin et al., 2003).  
The micellar core region often has one or multiple hydrophobic blocks which 
are commonly composed of polyesters, polyethers and poly(amino acid) 
derivatives. Derivatives of poly(amino acid) such as poly (L-aspartate) and 




of particular interest are FDA-approved polyesters, such as poly(ε-
caprolactone) (PCL) (Ukawala et al., 2012, Xiong et al., 2008, Xue et al., 
2012), poly(lactic acid) (PLA) (Ma et al., 2015), and poly(glycolic acid) 
(Mishra et al., 2011, Ouchi et al., 2002). The flexibility of using different 
hydrophobic blocks as the micellar core provides versatile and predictable 
properties of polymeric micelles for drug delivery. Controlled release of the 
drug from the micelle (temporal control) and site-specific delivery 
(distribution control) can be optimized through the choice of core and shell 
polymers. For example, PEG-b-PCL micelles allow solubilization of non-polar 
anti-cancer agents and slower drug release rates in comparison to PEG-b-PLA 
micelles. This is due to PCL being a semi-crystalline polymer, whereas PLA is 
an atactic and amorphous polymer (Ma et al., 2015, Sutton et al., 2007). Thus, 
the PCL chain is more compact due to enhanced intermolecular interactions 
and has a lower core polarity than PLA, resulting in a slower release rate of 
encapsulated drugs.  
One disadvantage of using micelles as drug carriers is the possibility of 
dilution of micelles to below their critical micellar concentration (CMC) 
during administration. This risk has been mitigated by synthesizing a highly 
stable surfactant with CMC below 10-6 M (Kabanov et al., 2002). The stability 
of micelles can be enhanced by increasing cohesive forces between the drug 
and the polymeric core segments such as hydrophobic force, hydrogen bond, 
and ionic interaction (Kim et al., 2010). By encapsulating hydrophobic drugs 




part of the copolymer may be enhanced, resulting in tightly packed and 
smaller cores. Moreover, the use of hydrophobic moieties that can form 
crystallized cores such as PCL, contributes to micelle stability and can confer 
greater drug retention by decreasing the release rate of the drug from the core 
(Ma et al., 2015). Cross-linking of the shell or core of micelles is another 
option to improve their stability (Yang et al., 2007). Another disadvantage of 
micelle drug delivery is early burst release of drugs which is a concern for 
physically-entrapped drugs (Gaucher et al., 2010). Burst release can be 
prevented by chemical conjugation of therapeutic agents or by cross-linking 
the micelles (Li et al., 2014).  
2.1.2  Nanogels 
Hydrogels are one of the most typical soft materials which have been widely 
investigated. Hydrogels are defined as cross-linked 3-D networks with 
hydrophilic polymer chains. This structure allows the hydrogels to swell in an 
aqueous environment and hold large amounts of water in the network, 
resulting in fluid-like transport properties (Nayak and Lyon, 2005). Hydrogels 
can be classified as physically cross-linked or chemically cross-linked 
hydrogels (Kabanov and Vinogradov, 2009). 
Nanogels, also called hydrogel nanoparticles, are a special class of the 
hydrogel family with size in the nanoscale. They would thus possess the 
combined features and characteristics of both hydrogels and nanoparticles. 
The cross-linked network endows them with stability that other nanostructures 




densely packed polymer inside the core structure. In contrast, nanogels are 
able to stably trap bioactive compounds such as drugs, proteins, and 
DNA/RNA inside their networks through electrostatic, van der Waals and/or 
hydrophobic interactions between the agent and the polymer matrix networks. 
Functionality can also be incorporated into the polymer backbone, cross-links, 
pendant groups, or on the surface of the nanogel for targeted delivery. 
In recent years, nanogels have attracted a high level of interest as a drug 
delivery system (DDS) for cancer therapy (Du et al., 2010, Hamidi et al., 2008, 
Raemdonck et al., 2009, Shen et al., 2013, Wu et al., 2010, Wu et al., 2011, 
Xiong et al., 2012, Yallapu et al., 2011). Matyjaszewski’s group has prepared 
well-defined and uniformly cross-linked biodegradable nanogels using atom 
transfer radical polymerization (ATRP) (Oh et al., 2006) and showed that 
these nanogels can potentially be drug delivery carriers (Oh et al., 2007, Oh et 
al., 2007). Feng et al. fabricated chitosan-based nanogels as a pH responsive 
carrier for oral delivery of doxorubicin (Dox) to the small intestine, with an 
absolute bioavailability of 42% in blood (Feng et al., 2013). Further 
investigations revealed that the components like chitosan (CS) are able to 
enhance intestinal adhesion and permeation, thus promoting the transport of 
Dox through the intestinal epithelium (Feng et al., 2014). 
A neutral polyacrylamide (PAm) nanogel has also been developed for optical 
nanosensors (Gao et al., 2008, Moreno et al., 2003, Park et al., 2003), contrast 
imaging (Kopelman et al., 2005) as well as in vitro and in vivo cancer-




nanoparticles offer many advantages compared to other forms of polymer-
based nanoparticles. PAm nanogels are hydrophilic networks which are very 
similar to biological tissues due to their high water content and soft, flexible 
consistency (Gao et al., 2008). PAm nanogels show minimal agglomeration or 
adsorption of proteins, due to their low interfacial tension and neutral surface 
charge. The preparation of PAm nanogels via water/oil microemulsion 
polymerization also offers size control during the synthesis process, as well as 
the ability to co-polymerize with other monomers to introduce additional 
functional groups. Polyacrylamide even at concentrations of 5 mg/ml does not 
cause significant decrease in cell viability after 24 hours (Gao et al., 2008). 
Furthermore, drugs loaded in PAm nanogel can be retained until they reach 
the intended sites where biodegradation of the cross-linker of the 
polyacrylamide nanogels in the targeted cells will result in the release of the 
drugs (Gao et al., 2008). Thus, this polymer coating is ideal for targeting 
cancer cells, without causing any undue damage to other parts of the body. 
Very recently, hybrid nanogels are increasingly being explored for loading 
with inorganic NPs, such as quantum dots (QDs) or/and metallic NPs (Wu et 
al., 2010, Wu et al., 2011). Wu et al. reported in-situ immobilization of CdSe 
QDs in CS-poly(methacrylic acid) (PMAA) nanogels. The nanogels were 
demonstrated to sense environmental pH change and regulate the release of 
anti-cancer drugs in a pH range of 5 to 7.4, which is typical of a tumor 
environment. Thus, these nanogels are promising for simultaneous 




2.1.3  Nanocapsules 
Nanocapsules are nano-vesicular systems with a typical core-shell structure, 
where active ingredients are confined to the cavity and protected by a polymer 
coating (Letchford and Burt, 2007, Mora-Huertas et al., 2010). The cores of 
these nanocapsules, with tank-like structure, are often lipophilic, although 
hydrophilic cavities have also been formed based on the preparation methods 
and materials used (Brigger et al., 2012). The active substance can be loaded 
in the cavity as a liquid or solid form or as a molecular dispersion (Mora-
Huertas et al., 2010). Active substances can also be adsorbed onto/into the 
surface shell of the nanocapsule. Based on their unique structure, it is 
generally accepted that nanocapsules possess high loading capability and can 
provide sustained release (Torchilin, 2006). Liposomes are spherical-shaped 
vesicles and consist of an internal aqueous compartment entrapped by the 
assembly of one or several phospholipid bilayers (Allen and Cullis, 2013). 
Based on their hollow structures shown in Figure 2.1, most liposomes can be 
generally classified as nanocapsules. Zong et al. have reported a dual-targeting 
Dox-loaded liposome with >90% loading efficiency to enhance drug 
penetration into the tumor, thereby improving the therapeutic efficacy against 
brain glioma (Zong et al., 2014). Shaikh et al. have achieved co-encapsulation 
of irinotecan and Dox in liposomes at a drug-to-lipid molar ratio of 0.8:1 
with >80% loading efficiency (Shaikh et al., 2013). In vivo experiments have 
revealed synergistic therapeutic benefits of the co-encapsulated formulation on 




Chitosan-poly(acrylic acid) (CS-PAA) nanocapsules, composed of an outer 
shell of protonated CS chains and an inner shell of CS-PAA polyelectrolyte 
complex, have been prepared using a core-template-free strategy (Hu et al., 
2004). Micellization happens via polyelectrolyte interaction when both CS and 
AA were dissolved in an aqueous solution and glutaraldehyde (GA), a bi-
functional cross-linker, was added to selectively crosslink CS. Further 
investigation has found that Dox could be encapsulated into the CS-PAA 
nanocapsules (Hu et al., 2007). The in vivo drug delivery of Dox-loaded 
nanocapsules maintained Dox concentration in blood for a longer period than 
free Dox solution. Hu et al. have also showed that these nanocapsules have the 
ability to deliver the drug to targeted organs, especially the liver (Hu et al., 
2007). 
2.1.4  Dendrimers  
Dendrimers are synthetic tree-like macromolecules, exhibiting 3D globular 
architecture with numerous dendritic arms branching out from a central core 
(Kesharwani et al., 2014). Dendrimers are characterized by monodispersity, 
well-defined molecular weight, nano-metric size range (1–100 nm), highly 
tailorable terminal surface and water solubility. Generally, they can be 
prepared using two methods: divergent (Tomalia et al., 1986) and convergent 
(Hawker and Frechet, 1990) synthesis, which are distinguished by the way the 
dendrimers are formed, with the former starting at the core, and the latter from 
the exterior. Dendrimers, with their unique properties, have attracted immense 




several advantages such as the ability to avoid macrophage uptake, targeting 
ability, easy cellular internalization and facile passage across biological 
barriers by transcytosis (Menjoge et al., 2010). The terminal surface with 
functional groups can be adapted to link drugs or antibodies for neutralizing or 
targeting purposes (Klajnert and Bryszewska, 2009, Menjoge et al., 2010). 
With modifications of the cavities inside the core and branches, successful 
encapsulation of hydrophobic or hydrophilic drugs can be attained (Mugabe et 
al., 2011). Therefore, dendrimers are promising platforms for drug attachment 
and binding via several mechanisms such as electrostatic interaction, physical 
encapsulation and covalent conjugation (Abbasi et al., 2014, Kesharwani et al., 
2014). A multifunctional platform of PEGylated polyamidoamine (PAMAM) 
dendrimer-stabilized Au nanorod with conjugated Dox in the dendrimer layer 
has been reported. This PAMAM-stabilized platform exhibited high 
therapeutic efficacy when used in combined photo-thermal and chemotherapy 
treatment, both in vitro and in vivo (Li et al., 2014). At present, FDA-approved 
products that involved the use of dendrimers have already been marketed for 
biomedical applications. The commercial SuperFect® (Qiagen, Germany), 
which is based on Tomalia-type PAMAM dendrimers, is widely used for in 
vitro gene transfection. Dendrimer-Gadomer MRI imaging agent is 
undergoing clinical trials by Bayer Schering Pharma AG. Stratus® CS, a 
cardiac marker diagnostic system containing PAMAM dendrimer-IgG 
antibody, has been commercialized by Dade Behring to reduce heart infarction 




2.1.5  Biopolymer-based Nanocarriers 
Biopolymers are attractive starting material for designing new soft 
nanomaterials, due to their non-toxicity, biodegradability, non-
immunogenicity, and availability from abundant sources. Biopolymers can be 
extracted from both plant and animal origins (Peng et al., 2012, Ragauskas et 
al., 2006) or obtained through biotechnology and synthetic technology, such 
as ring-opening polymerization (Deming, 2006, Kricheldorf, 2006) or solid-
phase synthesis (Plante et al., 2001). Another advantage of biopolymers is that 
the by-products from the degradation of biopolymers are very often non-toxic. 
The selective degradability of biopolymers by enzymes in the body, which is 
relevant to their specific sequence structure, is also useful for tailoring drug 
release by enzymatic degradation. The abundant functional groups in 
biopolymers can give rise to intra- and intermolecular physical interactions, 
such as hydrogen bonds and hydrophobic interactions, thus, offering a 
possibility for assembly into advanced constructs or incorporation of 
therapeutic molecules into the carrier (Neffe et al., 2013). Biopolymers used in 
formulation systems for anti-cancer drugs and gene delivery mainly consist of 
proteins, peptides, polysaccharides and nucleic acids.  
Generally, there are two main approaches in using protein-based biopolymers 
as delivery systems: conjugation of drugs directly to the protein or formulation 
of drug-protein nanoparticles. One of the major drawbacks of using free drugs 
for cancer treatment is the short half-life and transient drug retention within 




circumvent these issues. Albumin-drug conjugates, for example, have been 
demonstrated to improve in vivo efficacy, reduce systemic clearance and 
minimize systemic side effects (Lee et al., 2012). Within the systemic 
circulation, serum albumin is the most abundant protein and it has been well 
investigated for complexing with drug and nutrition molecules (Kratz, 2008, 
2014, Kratz and Elsadek, 2012). Plasma proteins are rapidly taken up by 
proliferating cancer cells to sustain their rapid growth (Schoonen and van Hest, 
2014), which further supports their action as carriers of therapeutic drugs 
through the blood circulatory system to cancer cells. Conjugation of drugs 
onto other proteins such as transferrin (Barabas et al., 1992, Lai et al., 2005, 
Lee et al., 2012), gelatin (Kushibiki et al., 2004, Matsumoto et al., 2006) and 
antibodies (Beck et al., 2010, Hughes, 2010) have also been reported.  
For protein-based nanoparticles, preparation strategies include desolvation 
(Langer et al., 2003, Weber et al., 2000), emulsification (Patil, 2003), thermal 
gelation (Yu et al., 2006) and nab-technology (Desai, 2007). It is noteworthy 
that nab-technology has been used to produce a FDA-approved drug, nab-
paclitaxel (Abraxane®), indicating that protein-based biopolymers have 
already been applied pre-clinically and clinically. Due to the different types of 
intra- and intermolecular interactions mentioned above, protein-based 
nanoparticles are able to facilitate effective incorporation of drug compounds. 
A previous study demonstrated that paclitaxel (PTX) in ethanol added as a 
desolvating agent to aqueous albumin solution, resulted in drug loading 




including plant derived proteins, such as gliadin, zein and soy protein, have 
also been used as drug carriers (Lohcharoenkal et al., 2014). For instance, 
gliadin, a gluten protein derived from wheat, has been explored for oral and 
topical drug delivery applications due to its inherent mucoadhesivity (Arangoa 
et al., 2000). Casein, a milk protein, exists as micelles of 100 to 200 nm in 
milk suspension and can be deemed as a natural nano-vehicle (Lohcharoenkal 
et al., 2014). Very recently, it was reported that cisplatin-loaded casein 
nanoparticles has the ability to penetrate cell membranes and target tumors 
(Zhen et al., 2013).  
Polysaccharide is another class of drug carrier that has been well studied. 
Polysaccharide-based nanoparticles are categorised into different classes 
according to their native charges: cationic (chitosan), anionic (alginate, 
heparin, hyaluronic acid) and non-ionic (pullulan, dextran). The 
aforementioned polysaccharides have hydrophilic groups such as hydroxyl, 
carboxyl and amino groups, which affect the polymer charges and can react 
with other molecules to endow further functionalization (Mizrahy and Peer, 
2012, Morris et al., 2010). The formation of polysaccharide-based 
nanoparticles can be obtained through mechanisms such as chemical and 
physical cross-linking, polyelectrolyte complexation and self-assembly 
(Mizrahy and Peer, 2012). 
Chitosan and alginate are two widely used families of polysaccharides. 
Chitosan is cationic in nature and exhibits a strong mucoadhesive property 




(Morris et al., 2010). In addition, chitosan was reported to increase cell 
membrane permeability, enhance absorption across intestinal epithelia and 
open the tight junctions of cell membranes (Roldo et al., 2004). Alginate is 
anionic in nature and undergoes a simple gelation process in the presence of 
cations such as Ca2+ and Pb2+. This principle has been widely exploited for 
encapsulation of cells, enzymes and bioactive molecules for biologics 
manufacturing (Shuler and Kargı, 1992). Alginate has also demonstrated its 
versatility for delivery of various therapeutic agents such as insulin, anti-
tubercular and anti-fungal drugs (Nitta and Numata, 2013).  
Currently, exploration of nucleic acid-based drug carriers is based on the 
concept of entropy-driven self-assembly of DNA into supramolecular 
structures (Seeman, 2003). Further tuning and engineering of the DNA 
sequence also allow DNAs to form micelles for drug encapsulation. This 
strategy has been demonstrated to effectively encapsulate a hydrophobic anti-
cancer drug into DNA-based micelles (Alemdaroglu et al., 2008). Also, DNA-
based materials are responsive to various stimuli such as light, pH, 
temperature, thus granting high versatility towards the design of intended 
trigger mechanism for drug release (Neffe et al., 2013). However, these DNA-
based biopolymers are very often hybrid-based biomaterials and their 
preparation and morphology control are highly dependent on pH, salinity, 
polymer concentration and solvent composition (Ding et al., 2007). As DNA 
block copolymer micelles may possibly disintegrate upon dilution in vivo, 




arises from the immunotoxicity at the target site, since this system would 
naturally result in a high local DNA concentration (Schnitzler and Herrmann, 
2012).  
 
2.2 Design Considerations for Chemotherapeutic Drug 
Delivery System 
2.2.1  Cancer Cell Targeting 
The primary challenge in cancer chemotherapy is to kill or control tumor cell 
growth without substantially compromising the viability of surrounding 
healthy cells. Hence, the concept of ‘therapeutic index’ (TI) becomes an 
important consideration in cancer chemotherapy. Therapeutic index is used to 
quantify the ratio of a therapy’s treatment potential in relation to its normal 
tissue toxicities (Giustini et al., 2010). It is clear that therapies with high 
therapeutic index are most preferable for clinical application. However, the 
close similarity between normal and neoplastic tissues makes it difficult to 
develop therapies that have the ability to differentiate between them. 
Nonetheless, in the current practice, chemotherapy employs two different 
types of targeting strategy: active targeting and passive targeting, which are 





Figure 2.2. Illustration depicting the difference between (A) free drug, (B) 
passive targeting and (C) active targeting [reproduced with permission from 
(MaHam et al., 2009)].  
 
2.2.1.1  Active Targeting 
The basis of active-targeting mainly relies on the specific binding affinities of 
the ligand to the targeted receptor site. With interest to achieve a high 
therapeutic index, the targeting ligand decorated onto the DDS has to be 
specific in targeting cancer cells, while sparing healthy cells. The mutation of 
genes within the cancer cells leads to overproduction of the receptors 
corresponding to these genes, while normal healthy cells have relatively lower 
amounts of these receptors. Some over-expressed receptors in cancer cells 
include luteinizing hormone-releasing hormone (LHRH) receptor, transferrin 
receptor, folate receptor (FR) and epidermal growth factor receptor (EGFR) 
(Liu et al., 2011, MaHam et al., 2009, Zwicke et al., 2012). Short peptide 
sequences have also been demonstrated to be able to target cancer cells. One 
example is the VPWMEPAYQRFL amino acid sequence for neuroblastoma 
targeting (Askoxylakis et al., 2006). However, small molecules have become 
more attractive than antibodies due to their small size, good stability and ease 




affinity for FRs which are aggressively expressed in certain types of cancers, 
including ovary, endometrium, breast, kidney, and myeloid cells of 
hematopoetic lineage (Franzen, 2011, Xia and Low, 2010). Thus, FA-
conjugated nanoparticles are a common and effective strategy for targeted 
delivery to tumors (Leamon and Reddy, 2004, Lu and Low, 2002, Ross et al., 
1994, Wang et al., 2011). It was also demonstrated that methotrexate (MTX), 
an analogue of FA, is able to act as both a targeting ligand and a 
chemotherapeutic agent for the treatment of FR-positive cancer cells (Castaldo 
et al., 2011, Chen et al., 2007, Zeng et al., 2001). The toxicity of MTX is due 
to the inhibition of enzymes required in the folate metabolic pathway, and the 
blocking of DNA synthesis, which leads to cell death (Castaldo et al., 2011).  
However, targeting cancer cells remains a huge challenge because cancer cells 
may develop resistance towards the therapeutic drugs. Resistance to MTX via 
intracellular efflux mediated by multidrug resistance proteins (MRPs) has 
been studied (Zeng et al., 2001). Nanoparticle-mediated targeting systems may 
enable the DDS to overcome such resistance. Chen et al. have demonstrated 
the affinity of MTX for Au NPs and the enhanced toxicity of MTX-Au NPs 
complex to various cancer cell lines, indicating the possibility of overcoming 
the cells' resistance to MTX (Chen et al., 2007).  
2.2.1.2  Passive Targeting 
Another targeted drug delivery strategy involves the use of passive, size-based 
accumulation and extravasation of drugs at tumor sites. It is reported that 




resulting in weak lymphatic drainage and leaky vascularization (Matsumura 
and Maeda, 1986). This gives rise to an enhanced permeability and retention 
(EPR) effect, which is the main basis for passive targeting. Particulate 
formulations of 10-500 nm in size could penetrate through the endothelial 
lining of tumor blood vessels and accumulate inside the interstitial space of 
tumors (Hobbs et al., 1998). EPR effect has greatly motivated the 
development of various soft nanoparticle-based carriers (reviewed in Section 
2.1) for the delivery of chemotherapeutic drugs.  
Moreover, the microenvironment surrounding tumor tissue is different from 
that of healthy cells, as the high metabolic rate of fast-growing tumor cells 
requires more oxygen and nutrients. Consequently, glycolysis is stimulated to 
obtain extra energy, resulting in an acidic environment (Pelicano et al., 2006). 
This physiological phenomenon is also widely used to support passive 
targeting delivery (Hanahan and Weinberg). pH-sensitive liposomes have been 
designed to be stable at physiological pH 7.4, but degrade to release drug 
molecules at acidic pH (Yatvin et al., 1980). More recently, pH-sensitive 
nanogels have also been developed for loading with drugs such as Dox and 
MTX (Salehi et al., 2015, Yang et al., 2015).  
Another alternative perspective that can be considered is direct local delivery 
of anticancer agents to tumors (Heath and Davis, 2008), which will bypass 
systemic circulation. This reduces the need for modifying nanoparticles to 
avoid renal or liver clearance. This kind of passive targeting delivery is often 




intravesical instillation (GuhaSarkar and Banerjee, 2010, Shen et al., 2008), 
which will be discussed in Section 2.3. 
2.2.2  Systemic Circulation Time 
In order to achieve either active or passive targeting delivery, there is a need 
for increasing the systemic circulation time of the drug formulations. 
Otherwise, the drugs will be removed from systemic circulation before they 
can exhibit anti-cancer efficacy, and accumulation of the drug formulations in 
the tumor environment will be reduced. In general, there are two major 
pathways in our body for removal of foreign substances from systemic 
circulation: renal clearance and hepatic clearance. 
Renal clearance occurs in the kidney – a functional organ, which removes 
wastes in our blood circulation and excretes them into the urine through a 
multi-faceted process. Glomerular filtration is the first and foremost event that 
occurs in the kidney and is able to remove nanoparticles with size <8 nm from 
systemic circulation (Choi et al., 2007). It was reported that the charges of the 
nanoparticles play a role in glomerular filtration with cationic nanoparticles 
being most easily filtered, followed by neutral nanoparticles. Anionic 
nanoparticles are the least readily filtered through the glomerular capillary 
wall (Deen et al., 2001, Ohlson et al., 2001). Thus, DDS with size of <8 nm or 
cationic nature is not desired for intravenous applications. 
Hepatic clearance occurs in the liver and the process is very effective and 
efficient in clearing small molecules and viruses of 10-20 nm in scale. 




or capture them through phagocytosis, followed by catabolism and breakdown 
of these foreign particles (Taylor-Robinson, 2003). Therefore, there is a need 
to modify drugs or drug-carrier complexes to reduce or prevent opsonisation, 
thereby reducing liver clearance. PEGylation is a well-known solution to 
reduce opsonisation (Choi et al., 2007, Veronese and Mero, 2008) and is 
widely used for nanoparticle-based DDS to circumvent liver clearance via 
phagocytic cells. Non-specific uptake by the reticuloendothelial system (RES) 
or mononuclear phagocytic system (MPS), e.g. macrophages, is the main 
pathway for rapid elimination of DDS from the circulatory system, and leads 
to high accumulation of DDS in the liver (i.e. hepatic clearance). The primary 
function of macrophages is to act as phagocytes that would clear foreign 
particles, bacteria and viruses which are opsonized (Haley and Frenkel, 2008, 
Wang et al., 2012). Macrophage evasion is one of the key issues for drug-
carriers to achieve effective delivery. It was shown that in order to maximize 
circulation times and targeting ability, the optimal size of nanoparticles should 
be <100 nm in diameter and the surface of these nanoparticles should be 
hydrophilic to circumvent clearance by macrophages (Nie et al., 2007). 
2.2.3  Stability and Biodegradation 
Another consideration in the design of DDS is stability and biodegradation. 
For intravenous system, the injection site could be potentially far from the 
targeted tumor. Thus, the issue of in vivo stability is often involved in many 




they undergo substantial dilution prior to administration or when they are 
diluted in vivo (Neffe et al., 2013). 
Biodegradation is another concern, as drug carriers have limited clinical use 
after unloading their cargos (Saini et al., 2004, Wahlberg et al., 1996). Their 
bioaccumulation at the target site may give rise to toxicity issues or other 
undesirable side effects. In this regard, the use of biopolymers would be 
advantageous as they are not only biodegradable, but also biocompatible. On 
the other hand, the degradation of drug carriers could be used to tailor the drug 
release rate. Flexibility in controlling the drug release profile is desired, as 
different release strategies and approaches may be preferred to treat diverse 
tumors (Sawyer et al., 2006).  
2.2.4  Drug Resistance and Combinatorial Therapy Strategies 
As mentioned in Section 2.1, cancer cells can develop drug-based resistance 
during the course of chemotherapy treatment. Imminent side effects from 
chemotherapeutic drugs are also unavoidable throughout the process of cancer 
treatment. Cisplatin (CDDP) and Dox are two commonly used anti-cancer 
drugs in clinical studies (Higgins, 2007, Hortobagyi, 1997, Kelland, 2007, 
Minotti et al., 2004), but their use is hindered by the development of drug 
resistance in cancer cells and severe side effects (Carvalho et al., 2014, 
Higgins, 2007, Kelland, 2007). Dox-induced cardiotoxicity is a major 
cumulative dose-limiting factor (Carvalho et al., 2014, Minotti et al., 2004), 
and CDDP causes nephrotoxicity and neurotoxicity, which often result in 




In view of the challenges faced in chemotherapy, combinatorial therapies may 
be advantageous for circumventing these problems (Weiss et al., 2015). 
Combinatorial therapies may include co-delivery of chemotherapeutic drugs 
(Greco and Vicent, 2009, Lane, 2006) or combined treatment regime using 
different cancer treatment modalities (Wilson et al., 2006).  
Combined chemotherapy, namely co-administration of two or more 
pharmaceuticals to capitalize on potential synergistic effects, has attracted 
much attention for effective and safe treatment of cancers (Arantes-Rodrigues 
et al., 2013, Greco and Vicent, 2009, Lane, 2006). Combination of cisplatin 
and sunitinib malate has shown a synergistic effect on bladder cancer cells 
(Arantes-Rodrigues et al., 2013). In principle, anti-cancer synergistic effects 
via co-delivery of two or more drugs are mainly due to different modes of 
action in suppressing tumor growth and thus preventing the development of 
drug resistance. Co-delivery of methotrexate (MTX) and mitomycin C (MMC) 
by PEGylated chitosan nanoparticles (CS-NPs) not only achieved high 
accumulation at the tumor site but also suppressed tumor cells growth more 
efficiently than the delivery of either drug alone (Jia et al., 2014). MTX, as a 
folic acid analogue, was also employed as a tumor targeting ligand and 
anticancer agent. In another study (Liu et al., 2014), PTX and Dox were 
loaded in a single cross-linked multilamellar liposomal vesicle (cMLV). The 
cMLV formulation is able to maintain specific drug ratios in vivo for >24 h, 
which enable the ratio-dependent combination synergy seen in vitro to 




Phase III trial has shown enhanced therapeutic effect on endometrial 
carcinoma (Thigpen et al., 2004). Earlier studies have shown that a 
combination of CDDP and PTX have synergistic effects which result in higher 
potency against NMIBC (Hadaschik et al., 2008). Gemcitabine, a nucleoside 
analog, has been widely used in combination with CDDP for the treatment of 
various cancers (Besancon et al., 2012, Moufarij et al., 2003, Valle et al., 
2010). It has been reported that gemcitabine inhibited the repair of CDDP-
induced DNA damage, by decreasing the expression of ERCC1 and XPA, two 
key proteins of the nucleotide excision repair (NER) system (Besancon et al., 
2012). Recently, ratiometric co-loading of gemcitabine monophosphate and 
CDDP in PLGA-PEG-anisamide NPs has been reported to exhibit synergism 
(Miao et al., 2014). In vivo tests of these gemcitabine monophosphate and 
CDDP co-loaded PLGA-PEG-anisamide NPs exhibited a more significant 
antitumor efficacy on a stroma-rich xenograft bladder tumor mouse model, 
compared to the drugs in free form or dual drugs loaded in a mixture of 
separate nanoparticles. A cocktail regimen with sequential weekly intravesical 
mitomycin-C, Dox, and CDDP has been reported to reduce the recurrent rate 
in patients with non-muscle invasive bladder cancers (NMIBCs) (Chen et al., 
2012).  
Combining chemotherapy with other cancer treatment modalities such as 
radiotherapy, thermotherapy and phototherapy has been demonstrated in the 




been also proven to overcome cancer drug resistance and reduce 
chemotherapy dosage.  
 
2.3 Bladder Cancer and Intravesical Drug Delivery 
2.3.1  Overview of Bladder Cancer 
More than 90% of bladder cancers are transitional cell carcinomas (TCC), 
which are malignant tumors arising from the transitional cells lining the 
urothelium of the urinary tract. Among the TCC cases, 70% are NMIBCs and 
30% are muscle-invasive bladder cancers (Houede and Pourquier, 2015, Pasin 
et al., 2008). Since the most prevalent form of bladder cancer is NMIBC, the 
work presented in subsequent chapters will focus on the development of soft 
nanoparticle-based chemotherapeutic DDS for potential NMIBC treatment. 
Bladder cancer is the 7th most common cancer and the 9th most common cause 
of cancer deaths in males (Jemal et al., 2011). In 2008, there was an estimate 
of 386,300 new diagnosed cases and 150,200 deaths caused by bladder cancer 
worldwide. The treatment of NMIBC mainly involves surgical transurethral 
resection of the tumors. However, tumor recurrence occurs in almost 70% of 
such treated cases, with around 10-20% progressing to a higher grade invasive 
disease (Anastasiadis and de Reijke, 2012). Therefore, follow-up treatment 
consisting of intravesical chemotherapy and immunotherapy is frequently used 




In spite of adjuvant therapies, the high recurrence rates and possible disease 
progression has contributed to bladder cancer having the highest lifetime 
treatment costs per patient across all types of cancers. This is because the 
typical treatment requires long term follow-up examination and long treatment 
duration (Rampersaud et al., 2010). Hence, there is a strong need for novel 
DDS in NMIBC treatment. 
2.3.2 Intravesical Drug Delivery 
The direct instillation of drugs into the bladder lumen via a catheter is known 
as intravesical drug delivery (IDD). This method allows for a more effective 
delivery of drugs as it bypasses systemic dilution and clearance of the 
intravenously administrated drug. Currently, intravesical drug delivery for 
bladder cancer treatment uses drugs such as mitomycin C, Dox, CDDP, and 
gemcitabine (Agarwal and Hussain, 2009, GuhaSarkar and Banerjee, 2010, 
Shen et al., 2008). The drug formulation may be a combination of several 





Figure 2.3. Illustration of bladder permeability barrier (BPB) established by 
the bladder urothelium and GAG layer that prevents adhesion [reproduced 
with permission from (Tyagi et al., 2006)].  
 
The structure of the urinary bladder wall in mammals comprises a number of 
layers, namely adventitia, muscularis, and mucosa that consists of lamina 
propria and transitional urothelium (Lewis, 2000). The urothelium, also known 
as bladder permeability barrier (BPB), covers the entire interior surface area of 
the bladder and acts as an impenetrable barrier between the blood and the 
urine (see Figure 2.3) (Tyagi et al., 2006). BPB also has an additional 
glycosaminoglycan (GAG)-layer or mucin-layer, which functions as an anti-
adhesive structure for pathogens and aggressive compounds found in urine 
(Poggi et al., 1999). The presence of BPB and the nature of the bladder as a 
short-term storage organ for urine have presented challenges in IDD, i.e. low 





2.3.2.1  Bladder Permeability 
A few strategies can be employed to increase drug permeability. One is a 
physical approach involving electromotive drug administration whereby a 
small electric current is applied on the bladder wall to enhance drug transport 
through the bladder wall (Giannantoni et al., 2006). Another physical method 
is hyperthermia, where heated drug formulations are instilled directly to 
stimulate better drug permeability and efficacy (Owusu et al., 2013). 
Alternatively, chemical approaches are available, such as using permeation 
enhancement chemicals and mucoadhesive materials which rely on 
interactions with the glycosaminoglycans which form a mucin layer covering 
the urothelium (Kos et al., 2006). Various biopolymers and soft-nanoparticles 
can be tailored to achieve mucoadhesivity. For instance, chitosan has been 
used as a permeation enhancer since cationic chitosan binds to the negatively 
charged mucin layer, loosening the tightly packed urothelial cells and resulting 
in enhanced permeability (GuhaSarkar and Banerjee, 2010, Shen et al., 2008).  
2.3.2.2  Drug Residence Time 
Short drug residence time is due to the nature of the bladder as a temporary 
storage organ for urine. Frequent emptying of the bladder presents a limitation 
on the residence time of instilled drugs within the bladder, and this increases 
the frequency and duration of treatment needed. The progressive dilution of 
instilled drugs due to continuous filling up of the bladder with urine is also 




2006). Thus, novel strategies for IDD that increase the residence time of 
therapeutic agents in the bladder are desired.  
One method of circumventing this problem is by using drug carriers such as in 
situ hydrogels, liposomes, and nanoparticles for prolonging the residence time 
of chemotherapeutic agents in the bladder (Giannantoni et al., 2006, 
GuhaSarkar and Banerjee, 2010, Mugabe et al., 2009, Shen et al., 2008). Such 
carriers usually possess the ability to be retained inside the bladder despite 
voiding of the bladder content during urination. One such method is by 
designing drug carriers with high mucoadhesivity to ensure a continuous 
release of the loaded drugs even after urine voiding (Smart, 2005).  
2.3.2.3  State-of-Art of IDD 
Recently, IDD for bladder cancer treatment has been investigated using 
various nano-formulations both in vitro and in vivo. Polymeric micelle 
formulations based on amphiphilic di- or tri-block copolymers of poly(3-
caprolactone)-b-poly(glycidyl methacrylate)-b-poly(poly(ethylene 
glycol)methyl ether methacrylate) (PCL-b-PGMA-b-P(PEGMA)), poly(ε-
caprolactone)-b-poly-(propargyl methacrylate-click-mercaptosuccinic acid-co-
poly-(ethylene glycol) methyl ether methacrylate) (PCL-b-P-(PMA-click-
MSA-co-PEGMA)), and (methoxy poly(ethylene glycol)-b-poly (D,L-lactic 
acid) (MePEG-PDLLA) have been exploited for delivery of Dox, CDDP, PTX 
or DTX to bladder cancers (Chen and Liu, 2014, Huang et al., 2012, Tsallas et 
al., 2011). In an ex vivo model using freshly excised porcine bladder tissue, 




PDLLA micelle formulations was demonstrated, compared to their 
commercial formulations, PTX in Cremophor EL/ethanol or DTX in Tween 
80. Furthermore, intravesical instillation of PTX (5 mg/ml in saline)-loaded 
MePEG-PDLLA micelles was tolerated with no adverse toxicity in mice 
(Hadaschik et al., 2008). In another study, intravesical nab-PTX was evaluated 
in a Phase II trial for the treatment of NMIBC after BCG treatment failure 
(McKiernan et al., 2014). The treatment was conducted by intravesical 
instillation of nab-PTX formulation on a weekly basis for 6 weeks, followed 
by a monthly basis for 6 months as maintenance in case of response. Of the 28 
patients enrolled in this trial, 35.7% had a complete response after the 6 weeks 
treatment, and after the maintenance therapy, these responses remained 
durable which is not frequently seen in any previous taxane-based clinical trial. 
Another system used for IDD is hydrophobically derivatized hyperbranched 
polyglycerol (HPG) nanoparticles loaded with DTX (Mugabe et al., 2011). 
C8/C10 alkyl chains were tethered onto these HPG cores to increase their 
hydrophobicity for the binding of hydrophobic drug (e.g. DTX). The surface 
modification of the HPG nanoparticles with amine groups endowed the 
nanoparticles with strong mucoadhesion on the bladder luminal surface 
(Mugabe et al., 2011), and thus increased the uptake of DTX in both isolated 
pig bladder tissues and in live mouse bladder tissues (Mugabe et al., 2012). 
The DTX-loaded amine-terminated HPG nanoparticles at a dose as low as 0.2 
mg/ml showed higher in vivo antitumor efficacy in an orthotopic model of 
bladder cancer, compared to commercial taxotere or neutral HPG loaded with 




derivatized HPG was also carboxylated for binding CDDPvia coordination of 
CDDP with the terminal carboxylate groups. These CDDP-bound HPG 
nanoparticles have been shown to be promising for effective inhibition of the 
proliferation of KU-7-luc bladder cancer cells (Ye et al., 2011). 
Other therapeutic modalities have also been exploited for bladder cancer 
treatment. A potential application of photodynamic therapy has been 
demonstrated using liposome-assisted delivery of tetramethyl 
hematoporphyrin (TMHP), a photosensitizer, into two human bladder cancer 
cell lines within 1 h of incubation (Bachor et al., 1995). Upon irradiation with 
red light, the TMHP-treated cells showed a high death rate. In another study, 
intravesical liposome-assisted interleukin-2 (IL-2) gene transfection in animals 
with pre-established novel orthotopic MBT-2 murine bladder tumor model 
was investigated (Horiguchi et al., 2000). A IL-2 lipoplex composed of 
cationic liposome, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl 
ammonium bromide (DMRIE), and neutral liposome, 
dioleoylphosphatidylethanolamine (DOPE), was used to transfect the gene of 
interest into growing bladder tumors. The survival rate is 40% in the group 
with intravesical IL-2 gene therapy after 60 days, compared to zero in the 
control groups treated with either parental blank or b-galactosidase lipoplex. 
2.3.3 Mucoadhesion 
Due to low drug permeability and short residence time, drug carriers should be 
designed with high mucoadhesivity to mitigate both problems simultaneously. 




capable of strong interactions with the mucin layer. It was reported that 
hydrophilic groups such as carboxyl groups, amine groups and hydroxyl 
groups are able to achieve mucoadhesion (Smart, 2005). The mucoadhesion 
mechanisms of the respective groups are different. Mucoadhesion can arise 
from interactions such as ionic interactions, hydrogen bonds and disulphide 
bonds (Smart, 2005).  
Mucins are glycoproteins with high-molecular weight from 0.5 to 40 MDa and 
their sub-units are linked together by peptide linkages and intramolecular 
cysteine–cysteine disulfide bridges (Peppas and Sahlin, 1996). Recently, 
thiolated groups were reported to have mucoadhesion properties because of 
the formation of disulphide bonds with the cysteine-rich subdomains of the 
mucin layer (Leitner et al., 2003, Shaikh et al., 2012). Most mucins are also 
net negatively charged (approximate pKa of 1.0–2.6) due to carboxylate 
groups (sialic acid) and ester sulfates present in their sub-units (Khutoryanskiy, 
2011). Due to the electrostatic attraction with negatively charged mucins, 
cationic polymers such as CS (Caramella et al., 2010, Zambito and Di Colo, 
2010) and some synthetic polymethacrylates (Keely et al., 2005) have been 
reported to exhibit excellent mucoadhesive behavior. CS is a well-established 
mucoadhesive positive polysaccharide used for oromucosal (Pedro et al., 
2009), oral (Chen et al., 2009), ocular (de la Fuente et al., 2010) and nasal 
(Illum, 2003, Kang et al., 2009) routes of administration. CS-based drug 
carriers have been also explored for enhancing the contact between drugs and 




al., 2011, Takeuchi et al., 2001, van der Lubben et al., 2001, Wittaya-areekul 
et al., 2006). However, there is evidence that CS may cause deterioration of 
the urothelium (Kos et al., 2006). Recently, more tolerable mucoadhesive 
materials with positive charges and good biocompatibility have been designed 
and evaluated for IDD application in bladder cancer chemotherapy (Carvalho 
et al., 2010, Hadaschik et al., 2008, Mugabe et al., 2009, Mugabe et al., 2011, 
Mugabe et al., 2012, Ye et al., 2011). 
In the following two chapters of this thesis, the design and evaluation of two 
kinds of mucoadhesive soft nanomaterials for potential intravesical therapy of 
bladder cancers are described. The tailoring of these nanomaterials as carriers 
was conducted for various therapeutic agents. The challenging issues which 
have to be addressed are low residence time and poor permeability of drug in 
the bladder, and the need for biocompatibility, sustained drug release and 












CHAPTER 3 MUCOADHESIVE 
POLYACRYLAMIDE NANOGEL AS A 
HYDROPHOBIC DRUG CARRIER FOR 





Treatment of NMIBCs is one of the costliest therapy due to its long-term 
propensity of recurrence (Botteman et al., 2003). Tumor recurrence occurs in 
almost 70% of the patients who are initially cured after surgical transurethral 
resection (TUR) (Shen et al., 2008). Chemotherapy via intravesical instillation 
of anticancer drugs has been used as adjuvant therapy. In intravesical therapy, 
the diseased sites are exposed to higher dosages with minimal systemic side 
effects compared to intravenous or oral therapy (GuhaSarkar and Banerjee, 
2010, Shen et al., 2008). As mentioned in Chapter 2, two characteristics of 
urinary bladder, however, present challenges for intravesical therapy. Firstly, 
the bladder permeability barrier (BPB) lining the luminal surface of the 
bladder prevents the efficient delivery of drugs into the tumors (GuhaSarkar 
and Banerjee, 2010). Secondly, the residence time of drugs in the bladder is 
short due to voiding of urine, and hence exposure of the intended sites to the 
drugs is reduced (Tyagi et al., 2006, Wirth et al., 2009). IDD via 
mucoadhesive carriers seems to be a promising strategy to address these issues. 
The use of mucoadhesive materials as drug carriers has been widely 
investigated (Andrews et al., 2009, Bernkop-Schnurch, 2000, Carvalho et al., 
2010, Mishra et al., 2010, Wittaya-areekul et al., 2006). Mucoadhesive 
polymeric drug carriers offer various benefits, such as being able to target a 
particular site in the body (so-called site-specific drug delivery), promoting the 
contact between the drug-loaded carrier and the mucosal layer, allowing for 
better tissue permeability of the drug and extending the drug residence time 




For intravesical chemotherapy, hydrophobic anticancer drugs offer a distinct 
advantage of greater permeability through the urothelium as compared to 
hydrophilic drugs. Paclitaxel, a commonly used active compound to treat 
various tumors, penetrates bladder tissue 20 times faster than hydrophilic 
drugs such as mitomycin C. This will allow longer retention of therapeutic 
doses within the bladder tissue even after the instilled solution is removed via 
urine voiding (Song et al., 1997). Docetaxel (DTX) has a structure similar to 
paclitaxel, and a Phase I trial result showed DTX to be a promising drug 
against superficial bladder cancer due to its low toxicity with little or no 
systemic absorption (Barlow et al., 2009, Barlow et al., 2009, McKiernan et 
al., 2006). However, due to the low solubility of hydrophobic drugs, their 
intravesical instillation often involves toxic agents such as dimethyl sulfoxide 
(DMSO), which results in painful therapy (Parkin et al., 1997). Hence, 
delivery of hydrophobic drugs via mucoadhesive drug carriers are highly 
desired. 
Herein, an amine-functionalized polyacrylamide nanogel (PAm-NH2) was 
developed as a carrier for hydrophobic drugs (using DTX as a model) and 
evaluated its potential for IDD application against bladder cancers. This 
strategy is illustrated in Figure 3.1. As reviewed in Section 2.1, nanogels are 
cross-linked 3D networks of hydrophilic polymers. They are more stable than 
micelles and their cargo can be unloaded via diffusion through the networks. 
Despite the many advantages of nanogels as DDS, they also suffer some 




and limited drugs suitable for loading. Although nanogels loaded with 
hydrophilic drugs are widely studied, those loaded with hydrophobic drugs are 
rarely reported. This is mainly due to the inherent immiscibility between 
hydrophobic and hydrophilic molecules, which causes difficulty in drug 
loading. PAm nanogels have been widely used in biomedical applications 
(Giuntini et al., 2012, Hamidi et al., 2008, Wang et al., 2012). However, one 
major concern is that conventional PAm hydrogels are neither biodegradable 
nor bioeliminable, and thus tend to accumulate in the body. In this study, drug 
loading in nanogels cross-linked with a degradable ester-containing cross-
linker was carried out in acetic acid, which served as a solvent for the drug and 
also facilitated the opening up of the nanogel network. The amine groups on 
the nanogels are expected to endow the nanogels with mucoadhesivity, which 
is a critical property in bladder-specific drug delivery. The mucoadhesivity of 
the nanogels was thoroughly evaluated in vitro and ex vivo. Endocytosis of the 
FITC-labeled nanogels by bladder cancer cells was investigated, and the 
killing efficacy of the DTX-loaded nanogels on two bladder cancer cell lines 





Figure 3.1. Schematic diagram illustrating the loading of DTX into nanogels 
and the concept of DTX-loaded PAm-NH2 nanogels as a potential intravesical 
drug delivery system for bladder cancer therapy. 
 
3.2 Materials and Methods 
3.2.1  Materials 
Docetaxel (DTX) was purchased from LC Labs (Woburn, MA). Acrylamide 
(Am), glycerol dimethacrylate (GDA), ammonium persulfate (APS), 2-




stomach), fetal bovine serum, L-glutamine, penicillin, 3-[4,5-dimethyl-thiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), 
fluorescein isothiocyanate (FITC), 4’,6-diamidino-2-phenylindole (DAPI) and 
alcian blue solution (1% in 3% acetic acid, pH 2.5) were purchased from 
Sigma-Aldrich (St. Louis, MO). Dulbecco’s Modified Eagle’s Medium 
(DMEM), RPMI-1640 medium was purchased from Invitrogen (Carlsbad, 
CA). Tetramethylethylenediamine (TEMED) and dioctylsulfosuccinate (AOT) 
were purchased from Alfa Aesar, and 3-(aminopropyl) methacrylamide 
(APMA) was obtained from Polysciences Inc. Hexane, ethanol, acetic acid 
and all other solvents were obtained from either Fisher Scientific or Sigma 
Aldrich. Artificial urine was prepared in accordance with the formulation 
reported in the literature (Brooks and Keevil, 1997) and the components are 




Table 3.1. Components of artificial urine used in this study. 
Componenta Concentration (g/l) 
magnesium chloride 
hexahydrate 0.65 
calcium chloride 0.49 
sodium chloride 4.6 
di-sodium sulphate 2.3 
tri-sodium citrate dihydrate 0.65 
di-sodium oxalate 0.02 
potassium dihydrogen 
phosphate 2.8 
potassium chloride 1.6 
ammonium chloride 1.0 
urea 25 
gelatin 5.0 
 a: The pH of the artificial urine was adjusted to 6.1 by adding HCl and then sterilized 
by membrane filtration before use. 
 
3.2.2  Preparation of Blank and DTX-loaded PAm-NH2 Nanogels 
Amine-functionalized PAm nanogels (PAm-NH2) were prepared via a 
water/oil (W/O) microemulsion polymerization method (Gao et al., 2008, Lu 
et al., 2013, Moreno et al., 2003). Briefly, AOT (1.6 g) and Brij 30 (3.2 g) 
were dissolved in 40 ml of hexane, and 2 ml of deionized (DI) water solution 
containing Am (0.61 g), GDA (0.3 g) and APMA (45mg) was emulsified into 
the prepared hexane solution, which resulted in a clear dispersion. The 
dispersion was vigorously stirred and bubbled with purified argon for 30 min. 




to initiate the polymerization at 30 ºC under argon atmosphere. After 12 h, the 
reaction was stopped by exposure to air and the solvent was then removed by 
rotary evaporation. The residue after solvent evaporation was washed with 
ethanol/water three times, followed by dialysis (using a cellulose membrane 
dialysis tubing of molecular weight cutoff (MWCO) of 12400 Da, Sigma) 
against DI water for 3 days. The solution was then freeze-dried using a 5 L 
ModulyoD freeze-dryer (Thermo Fisher Scientific, Waltham, MA) to obtain 
the dry samples. Non-amine-functionalized PAm nanogels (NA-PAm) were 
prepared in the same way except that APMA was not added.  
To load DTX into nanogels, PAm-NH2 nanogels (20 mg) were dispersed into 1 
ml acetic acid and stirred for a week. Preliminary experiments showed that 
this period of time was required to attain a high loading efficiency. 100 μl 
DTX in acetic acid (10 mg/ml) was then added into the nanogel dispersion. 
The mixture was sonicated for a few minutes and then stirred for 1 h, before 
the acetic acid (HAc) solvent was evaporated in a vacuum oven. The complex 
was then redispersed into DI water to obtain a dispersion that was generally 
clear. If a small amount of the drug was not loaded into the nanogels, a white 
precipitate would be present. Sonication was then carried out with a probe 
sonicator (Branson Sonifier 250) for several minutes followed by 
centrifugation at 9000 RPM for 10 min. The clear supernatant, containing the 
nanogels with loaded DTX (PAm-NH2-DTX), was transferred into a new tube 
and freeze dried. The loading efficiency of DTX was calculated to be >90% by 




amount of DTX used. The amount of DTX in the precipitate was determined 
using an ACQUITY high performance liquid chromatograph (HPLC, Waters, 
Milford, MA) coupled to an micrOTOF-Q electrospray ionization mass 
spectrometer (ESI-MS, Bruker, Billerica, MA), which will be discussed in 
greater detail below. DTX loaded non-amine-functionalized PAm nanogels 
(NA-PAm-DTX) were prepared in a similar manner. In order to determine the 
effect of HAc on the nanogels, PAm-NH2 nanogels without DTX were also 
dispersed into 1 ml HAc for a week, and then dried in a vacuum oven and 
freeze-dryer. These blank PAm-NH2 nanogels were used as a control. 
3.2.3  Conjugation of FITC onto PAm-NH2 Nanogels 
To prepare FITC-labeled PAm-NH2 nanogels (FITC-PAm-NH2), 0.25 mg 
FITC was added into 10 ml PAm-NH2 dispersion (5 mg/ml) in PBS (pH 7.4), 
and the reaction mixture was stirred overnight. After that, the unreacted FITC 
was removed using an Amicon ultrafiltration cell (Amicon Ultra-15, 30 kDa 
filter cutoff, Millipore Corp., Bedford, MA), and the FITC-labeled nanogels 
were washed three times until the filtrate contained no fluorescent signal of 
FITC. The FITC-labeled sample was then freeze-dried using a 5 L ModulyoD 
freeze-dryer. 
3.2.4  Sizing and Zeta Potential Analysis 
A JEOL 2100F transmission electron microscope (JEOL, Tokyo, Japan) was 
used to observe the morphology and size of blank and DTX-loaded nanogels 
at an accelerating voltage of 200 kV. The specimens for transmission electron 




nanogel dispersion (concentration of 1 mg/ml) on a copper grid coated with a 
thin film of carbon. The DTX-loaded nanogels on the grid were stained with 
2% (w/v) phosphotungstic acid (PTA) aqueous solution for 15 min to enhance 
the contrast of the TEM images. The hydrodynamic size and zeta potential (ζ) 
of the nanogels in water were determined using a Zeta-sizer nanosystem 
(Malvern Instruments Corp., Worcestershire, UK). The dynamic light 
scattering (DLS) measurement was conducted with a 22 mW He-Ne laser 
(λ=660 nm) at a scattering angle of 90°. Each measurement was repeated at 
least three times and the results were reported as average ± standard deviation.  
3.2.5  Evaluation of Mucoadhesivity via Mucin-particle Method 
Mucoadhesive properties of nanogels (PAm-NH2 and NA-PAm) were 
investigated using the mucin-particle method (Huang et al., 2012, 
Thongborisute and Takeuchi, 2008). This method is based on the change in 
particle size due to interaction between submicrometer-sized mucin and 
adhesive polymers/particles. In brief, commercial mucin was suspended in 
acetate buffer (pH 4.5, 10 mg/ml) and incubated at 37 ºC overnight. The 
suspension was then sonicated with a probe sonicator for 30 min and 
centrifuged at 4000 rpm for 30 min. The supernatant was collected and the 
size of mucin particles was determined to be less than 200 nm. For the 
mucoadhesion study, the nanogel dispersion (5 mg/ml, NA-PAm or PAm-NH2) 
was mixed with an equal volume of the mucin suspension, vortexed and 




Zetasizer nanosystem. Each test was performed in triplicate and chitosan (10 
mg/ml, 0.1% acetic acid) was used as a positive control. 
3.2.6  Determination of DTX Release from PAm-NH2-DTX Nanogels 
To determine the kinetics of DTX release from the PAm-NH2-DTX nanogels, 
a dialysis method was applied. In brief, 8 mg PAm-NH2-DTX nanogels (equal 
to ~400 μg) in 2 ml DI water were transferred into a dialysis membrane bag 
(MWCO = 12000), and were dialyzed against 20 ml artificial urine (pH 6.1, 
containing 0.1% Tween 80) with shaking at 100 rpm at 37 ºC. At each selected 
time point, the entire release medium outside the dialysis bag was collected 
and replaced with the same volume of fresh medium. After the collected 
medium was freeze-dried, the released DTX was dissolved in acetonitrile and 
quantified using HPLC/UV-vis. For this analysis, a C18 column (Waters 
Nova-Pak, Milford, MA) was used with a mobile phase of a mixture of 
acetonitrile and water (60:40, v/v) at a flow rate of 1 ml/min. The injection 
volume was set to 20 μl, and the total run time was 20 min. The detection of 
DTX molecules was conducted using UV-vis detector at 232 nm. A standard 
curve of DTX in the concentration range of 0.5-50 μg/ml was established. The 
data was expressed as cumulative percentage of drug released as a function of 
time. Each test was performed in triplicate. 
3.2.7  Cell Culture 
Human urothelial carcinoma cell lines, UMUC3 and T24 (ATCC, Manassas, 




with 10% fetal bovine serum (FBS), 1 mM L-glutamine and 1% penicillin. 
The culture was maintained at 37 ºC in a humidified 5% CO2 atmosphere. 
3.2.8  In vitro Efficacy of DTX and DTX-loaded into Nanogels against 
Bladder Cancer Cells 
The cytotoxicity of DTX or DTX-loaded nanogels (PAm-NH2-DTX and NA-
PAm-DTX) was evaluated by determining the viability of T24 and UMUC3 
cells after exposure to medium containing the free drug or drug-loaded 
nanogels at DTX concentrations ranging from 0.01 to 2000 ng/ml. Free DTX 
in medium was prepared by first dissolving the hydrophobic DTX in DMSO 
(50 mg/ml) and this solution was added into medium to achieve the desired 
concentration. The amount of DMSO added to the medium was estimated to 
be at most 0.004%. It has been reported that 0.1% DMSO caused little or no 
cell damage (Matsui et al., 2002, Qi et al., 2008), and in particular for 
UMUC3 cell line, 0.45% DMSO did not result in adverse effects (Pereira et al., 
2014). Thus, it can be assumed that the amount of DMSO added to the 
medium would not affect the cytotoxicity of the cells. A standard MTT assay 
was used to test cell viability with minor modifications. 4000 or 5000 cells per 
well were seeded in a 96-well plate with 100 μl medium for T24 and UMUC3 
cells, respectively. After incubation for 24h, the medium in each well was 
aspirated off and the cells were exposed to 100 μl of fresh medium containing 
the drug/nanogels at various concentrations for 4 h or 72 h. The cells after 4 h 
treatment were further cultured for 72 h in fresh medium. After that, the 




MTT solution (5 mg/ml in PBS), followed by 4 h incubation at 37 ºC. After 
the medium was removed, the formazan crystals at the bottom of each well 
were dissolved with 100 μl of DMSO for 15 mins. The optical absorbance at 
560 nm was measured on a microplate reader (Tecan GENios, Männedorf, 
Switzerland). The results were expressed as percentages relative to the optical 
absorbance obtained in the control experiments which were carried out using 
the culture medium without drug and nanogels. 
3.2.9  Cellular Uptake of FITC-PAm-NH2 Nanogels 
To visualize the cellular uptake of FITC-PAm-NH2 nanogels, the cells 
(UMUC3 and T24) were seeded at a density of 5×105 cells per well in 6-well 
culture plates containing a cover slip on the bottom of each well for 24 h. 1 ml 
medium containing 0.05, 0.5 and 1 mg/ml FITC-PAm-NH2 nanogels was then 
added to each well, followed by 4 h incubation at 37 ºC. After the medium was 
removed, the cells were washed three times with PBS (pH 7.4) to remove the 
unattached nanogels and fixed with 4% formaldehyde for 15 min at 37 ºC. 
After washing with PBS, the cells on the cover slip were transferred onto a 
glass slide and stained with 4’, 6-diamidino-2-phenylindole (DAPI, 1 μg/ml) 
for 15 min. The cells were observed using a fluorescence microscope with 
DAPI/FITC filters (Zeiss LSM 510 Meta, Germany) and an Olympus FV1000 
confocal laser-scanning microscope (CLSM, 365 nm and 488 nm excitation). 
Another experiment was conducted using UMUC3 cells incubated with 0.5 
mg/ml FITC-PAm-NH2 nanogels for 4 h at 4 ºC for comparison with the 




also conducted whereby UMUC3 cells were incubated with 0.5 mg/ml FITC-
PAm-NH2 nanogels for 4 h at 4 ºC followed by further incubation with fresh 
medium for 4 h at 37 °C. 
3.2.10  Bladder Tissue Preparation and Mucoadhesivity Study 
Freshly excised urinary bladders from pigs were bought at a commercial 
abattoir and transported on ice to our laboratory within 60 min of sacrifice. 
Once the bladder arrived, the experiments were started immediately. The 
bladder was cut longitudinally into left and right lateral sides and excess 
adipose tissue on the exterior wall was removed. The tissue was then divided 
into pieces of approximately 5 cm × 5 cm and mounted onto a customized 
well-plate setup (illustrated in Figure 3.2), where only the inner surface of 
bladder walls was exposed to the sample solution. The bladder pieces were 
incubated with PBS (control), 1 mg/ml or 5 mg/ml FITC-PAm-NH2 nanogels 
(in PBS) at 37 ºC for 4 h. Following incubation, the solutions were removed 
and the tissue pieces were washed three times with PBS. The luminal surface 
of bladder wall was then monitored using an Olympus FV1000con focal laser-
scanning microscope (CLSM, 10-× observation, 488 nm excitation). To 
identify the mucin layer, which comprises glycosaminoglycans (GAGs), the 
prepared bladder pieces after treatment with FITC-PAm-NH2 nanogels were 
stained with alcian blue solution for 0.5 h. After the staining solution was 
removed, the bladder pieces were washed at least 3 times with DI water. The 
stained luminal surface was then observed using a fluorescence microscope 





Figure 3.2. Illustration of porcine bladder tissue piece fixed on a customized 
well-plate (mucoadhension assay setup) with a sandwich-like structure.  
 
3.2.11  Ex vivo Effect of PAm-NH2 on Morphology of Bladder 
Urothelium 
To examine the effect of nanogels on the urothelium, the morphology of the 
bladder luminal surface was observed using a 5600LV scanning electron 
microscopy (SEM, JEOL, Tokyo, Japan). Briefly, freshly excised porcine 
urinary bladders of 5 cm × 5 cm was mounted onto the customized well-plates 
and exposed to PBS (control), 5 mg/ml PAm-NH2, 5 mg/ml NA-PAm, or 0.2 
mg/ml or 1 mg/ml chitosan (positive control) at 37 ºC for 4 h. Following 
incubation, the tissue pieces were washed three times with PBS and flooded 
with a solution of 4% glutaraldehyde in PBS for 0.5 h at 4 ºC. The tissues 
were then dehydrated in ethanol solutions with increasing concentrations (30-
100%), followed by immersion into liquid nitrogen for quick freeze. After the 
tissues were freeze-dried, they were coated with platinum particles of ~5 nm 





3.3 Results and Discussion 
3.3.1  Preparation of PAm-NH2 Nanogels and Loading of DTX  
The PAm-NH2 nanogels were synthesized via W/O microemulsion 
polymerization initiated by APS/TEMED (Moreno et al., 2003). The blank 
PAm-NH2 nanogels are uniform and round. The hydrodynamic diameter as 
determined from DLS is about 41±3 nm, which is consistent with the TEM 
results. 
DTX was loaded into the PAm-NH2 nanogels via a very simple and 
environmentally friendly method as shown schematically in Figure 3.1. The 
as-prepared nanogel-DTX complex containing ~5 wt% DTX can be 
redispersed in PBS or water without precipitation at DTX concentration of 1 
mg/ml, indicating enhanced solubility compared to free DTX (<5 μg/ml) 
(Chen et al., 2008, Engels et al., 2007). The loading efficiency of DTX into 
PAm-NH2 nanogels was determined to be more than 90% by HPLC/ESI-MS. 
TEM images in Figure 3.3b show that the DTX-loaded PAm-NH2 nanogels 
(PAm-NH2-DTX) are more than 100 nm in size, which is surprisingly much 
bigger than the blank nanogels (~40 nm as shown in Figure 3.3a and Figure 
3.4a). The DLS result in Figure 3.3c shows that the average size of the PAm-





Figure 3.3. TEM images of PAm-NH2 nanogels without DTX (a) and with 
loaded DTX (b). DTX-loaded PAm-NH2 nanogels were stained with 2% (w/v) 
PTA aqueous solution to enhance the contrast. (c) Dynamic light scattering 
and (d) zeta potential results of DTX-loaded PAm-NH2 nanogels.  
 
 
Figure 3.4. (a, b) Dynamic light scattering and (c, d) zeta potential results of 





To determine what affected the size of nanogels during drug loading, blank 
PAm-NH2 nanogels were treated with acetic acid in a similar manner as the 
process of DTX loading. The TEM and DLS results in Figure 3.5a and 
Figure 3.4b show that after HAc treatment, PAm-NH2 nanogels became much 
bigger than their original size, and similar to PAm-NH2-DTX. This suggests 
that the size change of nanogels is not due to DTX but to the HAc solvent. 
Furthermore, both PAm-NH2-DTX and acetic acid-treated blank PAm-NH2 
nanogels became less regular in shape, compared to the original nanogels 
(Figure 3.3a). Since the ester bonds of the cross-linker (GDA) in the PAm 
nanogels were reported to be degradable in acidic or basic environment 
(Hamidi et al., 2008, Wang et al., 2012), the HAc solvent could have partially 
reacted with these ester bonds via a replacement reaction mechanism, which 
opened up the nanogel network to the drug molecules as shown in Figure 3.1. 
If the incubation time for nanogels in HAc was reduced to 1 or 2 days, the 
loading efficiency decreased to 10-30%. As the HAc-treated nanogels swelled 
from 40 nm (Figure 3.4a) to >100 nm (Figure 3.4a), their morphology cannot 
be clearly observed under TEM due to their low density. After staining with 
PTA, they can be observed under TEM (Figure 3.5). The reaction between the 
ester bonds in the nanogels and HAc molecules would produce new ester 
bonds and thus the ester bonds would not be depleted. The ester bonds are 





The ζ value of PAm-NH2 nanogels is 14.2±0.8 mV (Figure 3.4c), indicating 
that the amine groups render these PAm-NH2 nanogels positively charged, 
since the NA-PAm nanogels are neutral (0.9±0.5 mV). The ζ value of PAm-
NH2-DTX is 7.5±0.3 mV (Figure 3.3d), which is similar to that of HAc-treated 
PAm-NH2 nanogels (8.6±0.5 mV, Figure 3.4d). Since amine groups can react 
with carboxyl groups, there may be a reaction between amine groups and HAc 
during the incubation process, resulting in the decreased ζ. However, this 
reaction is unlikely to be the main reason for the change in size of the HAc-
treated PAm-NH2 nanogels since NA-PAm nanogels without amine groups 
also increased in size after HAc treatment (Figure 3.5b). DTX loaded NA-
PAm nanogels (NA-PAm-DTX) were also prepared and the ζ value was 
determined to be 1.1±0.7 mV, which is similar to that of NA-PAm nanogels. 
 
Figure 3.5. TEM images of PAm-NH2 (a) and NA-PAm (b) nanogels after 
HAc treatment without DTX. The HAc-treated nanogels were stained with 2% 
(w/v) phosphotungstic acid (PTA) aqueous solution for 15 min prior to the 
observations to enhance the contrast. 
 




The mucoadhesivity of the nanogels (PAm-NH2 and NA-PAm) was verified 
using the mucin-particle method (Huang et al., 2012, Thongborisute and 
Takeuchi, 2008) by monitoring changes in the particle size of mucin after 
incubation with nanogel solutions. Chitosan, a well-known mucoadhesive 
polymer, was used as a positive control. As shown in Figure 3.6, the 
hydrodynamic diameter of a mixture of mucin (10 mg/ml) and PAm-NH2 (5 
mg/ml) is >4.5 fold larger than that of the submicron-sized mucin alone (10 
mg/ml). Since mucin is negatively charged (Smart, 2005), the increase in 
particle size is attributed to electrostatic interactions between mucin and the 
amine groups in the PAm-NH2 nanogels which can be partially protonated in 
acidic or neutral environment. In other words, the positive amine groups 
endow the PAm-NH2 nanogels with mucoadhesivity. In contrast, incubation of 
NA-PAm nanogels, which have no amine groups, with mucin results in almost 
no increase in particle size. Such mucoadhesive behavior induced by positive 
charges was also demonstrated by the positive control, chitosan (>2-fold size 
increase as shown in Figure 3.6), as well as in other studies (Takeuchi et al., 
2005, Thongborisute and Takeuchi, 2008). However, it is not possible to 
incorporate hydrophobic drugs such as DTX in chitosan and thus it cannot 
qualify as a hydrophobic drug delivery system for bladder cancer therapy. 
On the other hand, the PAm-NH2-DTX nanogels are also mucoadhesive, as 
shown in Figure 3.6. Even though the ζ value of PAm-NH2-DTX is about half 
of that of PAm-NH2, the hydrodynamic diameter of a mixture of mucin (10 




NH2 nanogels (~4 fold bigger than that of the submicron-sized mucin alone 
(10 mg/ml)). This indicates that the PAm-NH2 retained its mucoadhesive 
property after DTX loading. 
 
Figure 3.6. Mucoadhesive properties of nanogels (PAm-NH2, PAm-NH2-DTX 
and NA-PAm) as evaluated by the mucin-particle method. Equal volumes of 
nanogel solution (5 mg/ml) and submicron-sized mucin were mixed, vortexed 
and incubated at 37 ºC for 30 min. Changes in particle size were monitored by 
light scattering measurements. Each test was performed in triplicate and 
chitosan (CS) (10 mg/ml in 0.1% acetic acid) was used as a positive control. 
 
3.3.3  DTX Release from Nanogels 
The release of DTX from PAm-NH2-DTX nanogels was evaluated using a 
dialysis method at 37 ºC. Artificial urine (pH 6.1) containing 0.1% Tween 80 
was chosen as the release media and the release medium was regularly 
replaced to provide the sink condition. The interaction of PAm-NH2 nanogels 
with the dialysis membrane was not observed after dialysis of the blank 
nanogels (labeled with FITC) for >10 days in a preliminary experiment, as 




shows that the first 9 h constitutes a rapid release phase and this is followed by 
a slow release phase over 9 days in artificial urine. After 9 days, ~70% of the 
DTX has been released from PAm-NH2-DTX nanogels into artificial urine. 
The rapid release phase, often called burst release, is a common phenomenon 
in drug delivery systems. It is likely due to the DTX molecules located on or 
close to the surface of the nanogels which are more easily released. In the 
acidic and high ionic strength environment of artificial urine, the positive-
charged PAm-NH2-DTX nanogel may swell to facilitate the burst release. It 
can be seen in Figure 3.7 that after 9 h, >30% of the loaded DTX has been 
released in artificial urine. The release of the hydrophobic DTX molecules that 
diffused from the interior of the stable nanogels through the hydrophilic 
matrix constitutes a sustained slow release phase (9 h to 9 days). This is 
reasonable as hydrophobic interactions are the main driving force for loading 
DTX into PAm-NH2 nanogels, and these interactions sustained its slow release 
as well. The sustained release of DTX over 3-14 days has also been reported 
in the literature (Dou et al., 2014, Wang et al., 2015). The release profiles 






Figure 3.7. Cumulative DTX release from PAm-NH2-DTX nanogels in 
artificial urine (A.U.) at 37 ºC. 
 
3.3.4  In vitro Killing Efficacy of DTX-Loaded PAm-NH2 Nanogels 
The cytotoxicity of free DTX and DTX-loaded nanogels (NA-PAm-DTX and 
PAm-NH2-DTX) was investigated using the MTT assay. Two human 
urothelial carcinoma cell lines, UMUC3 and T24, were chosen as they 
represent different kinds of bladder cancer: non–muscle invasive and muscle 
invasive, respectively. The cytotoxicity evaluation was carried out with either 
4 h or 72 h exposure to the free drug or drug-loaded nanogels. For the 4 h-
exposure experiments, cells were cultured in fresh medium for another 72 h 
after exposure to the free drug or drug-loaded nanogels before cell viability 
was determined. In all cases, the results showed concentration-dependent 
inhibition of the proliferation of both types of cancer cells (Figure 3.8). 




both cells is similar to free DTX, indicating that the pharmaceutical effects of 
DTX were not affected by its incorporation into the nanogels.  
 
Figure 3.8. In vitro viability of T24 cells (a, b) and high-grade human 
urothelial carcinoma cell lines (UMUC3 cells) (c, d) after exposure to NA-
PAm-DTX, PAm-NH2-DTX or DTX at different concentrations for 4 h or 72 
h. The cells after 4 h treatment were further cultured for 72 h in fresh growth 
medium. Control experiments were carried out without nanogels and DTX. 
Cell viability is expressed as % of control. Data shown is the average of at 
least 3 independent experiments. 
 
In Figure 3.8(a, b), the trends of concentration-dependent cytotoxicity against 
T24 cells are similar for 4 h and 72 h exposure time, but higher efficacy was 
observed for 72 h exposure. For UMUC3, Figure 3.8(c, d) shows that these 
cells are more sensitive to DTX than T24. For T24, IC50 of DTX in PAm-NH2-




the corresponding value for UMUC3 (5.6 ng/ml). When the exposure time is 
increased to 72 h, the difference in the IC50 values decreased to a factor of 7 
(11.6 ng/ml for T24 versus 1.6 ng/ml for UMUC3). Control nanogels (PAm-
NH2 without DTX) showed no cytotoxicity over the tested concentration range 
(0~200 μg/ml; Figure 3.9). As will be shown in the next section, the uptake of 
PAm-NH2 nanogels by UMUC3 and T24 cells is similar. Hence, the higher 
cytotoxicity of DTX or DTX-loaded nanogels on UMUC3 indicates that the 
UMUC3 cell line is more sensitive to DTX than T24 cell line. Thus, the DTX 
and DTX-loaded nanogels may be better candidates against NMIBC, like 
UMUC3. 
 
Figure 3.9. In vitro viability of T24 cells and high-grade human urothelial 
carcinoma cell lines (UMUC3 cells) after exposure to PAm-NH2 of different 
concentrations for 72 h. Control experiments were carried out without 
nanogels. Cell viability is expressed as % of control.  
 
3.3.5  Cellular Uptake of FITC-PAm-NH2 Nanogels 
PAm-NH2 nanogels labeled with FITC (FITC-PAm-NH2) were used to 




PAm-NH2 (13.5±0.9 mV) is comparable with that of PAm-NH2, consistent 
with the small amount of FITC used in the labeling process (feed molar ratio 
of amine group to FITC is >21). The uptake of FITC-PAm-NH2 nanogels by 
UMUC3 and T24 cells after exposure to different concentrations of nanogel 
solution for 4 h was examined by fluorescence microscopy. As shown in 
Figure 3.10a, high fluorescence can be observed from the images of UMUC3 
cultured with the nanogels at 1 mg/ml. Since the FITC fluorescence was 
distributed around the cell nuclei stained by DAPI, it can be concluded that the 
amine-functionalized nanogels were taken up by the cells to a significant 
extent. The electrostatic interactions between the positively charged FITC-
PAm-NH2 and the negatively charged components on the cell membranes may 
have facilitated the cellular uptake of the nanogels. With decreasing 
concentration of nanogel in the culture medium, the fluorescence signal in the 
cells gradually weakens. This demonstrates a concentration-dependent uptake 
of nanogels into UMUC3 cells at concentrations between 0.05-1 mg/ml. As is 
shown in Figure 3.10b, the concentration dependence and extent of cellular 
uptake of FITC-PAm-NH2 by T24 is qualitatively similar to that of UMUC3. 
To verify the internalization of FITC-PAm-NH2 nanogels by the cancer cells, 
CLSM images of UMUC3 cells cultured with 0.5 mg/ml nanogels at 4 ºC and 
37 ºC are compared in Figure 3.11. Endocytosis, an energy-dependent 
process, is expected to be inhibited at 4 ºC. Green fluorescence was observed 
at the periphery of the cells cultured with nanogels at 4 ºC, indicating that the 
FITC-PAm-NH2 nanogels only bound onto the outer surface of the cells. This 




PAm-NH2 and the negatively charged components on the cell membrane. In 
contrast, green fluorescence was observed inside the cells after incubation 
with 0.5 mg/ml or 1 mg/ml nanogels at 37 ºC. These results provide solid 
evidence of endocytosis of the positively charged FITC-PAm-NH2 nanogels at 
37 ºC. Endocytosis was further confirmed using a pulse/chase protocol, 
whereby UMUC3 cells were first exposed to medium containing FITC-PAm-
NH2 nanogels at 4 ºC for 4 h and then to fresh medium without the nanogels 
for another 4 h at 37 ºC. The results of the pulse/chase protocol are shown in 
Figure 3.12. It can be seen that the green fluorescence at the outermost 
surface of the cell after 4 h incubation at 4 ºC (Figure 3.12b) has migrated 
inside the cells after incubation in fresh medium at 37 ºC (Figure 3.12c), 
which is similar to the case when the cells were incubated with the nanogels at 
37 ºC for 4 h (Figure 3.12a). This indicates that FITC-PAm-NH2 which was 
bound on the outer membrane of the cells after 4 h incubation at 4 ºC was 










Figure 3.10. Fluorescence microscopy images of UMUC3 (a) and T24 (b) 
cells after culturing in medium containing 1 mg/ml, 0.5 mg/ml, and 0.05 
mg/ml FITC-PAm-NH2 nanogels for 4 h at 37 °C. Control experiment were 
carried out with PBS. For each panel, the images from left to right show cell 
nuclei stained by DAPI (blue), FITC-PAm-NH2 nanogels (green), and overlay 






Figure 3.11. CLSM images of UMUC3 cells after culturing in medium 
containing 1 mg/ml or 0.5 mg/ml FITC-PAm-NH2 nanogels at 37 ºC and 0.5 
mg/ml FITC-PAm-NH2 nanogels at 4 ºC for 4 h. Control experiment were 
carried out with PBS at 37 ºC. For each panel, the images from left to right 
show cells under FITC channel (green), DAPI+FITC merged channels 
(blue+green), and overlay of the three DAPI+FITC+bright field channels, 






Figure 3.12. Volume view CLSM images of UMUC3 cells after culturing in 
medium containing 0.5 mg/ml FITC-PAm-NH2 nanogels for 4 h at 37 ºC (a), 4 
h at 4 ºC (b), and 4 h at 4 °C followed by another 4 h at 37 ºC in fresh medium 
(c). Control experiment was carried out with PBS at 37 ºC (d). 
 
3.3.6  Ex Vivo Evaluation of Mucoadhesivity of FITC-PAm-NH2 on the 
Bladder Wall 
In order to simulate the instillation of PAm-NH2 nanogels into the bladder, 
porcine bladder was used to study the interaction of the nanogels with the 
urothelium, which is the epithelium that lines the luminal surface of the 
bladder. FITC-PAm-NH2 nanogel solution was incubated with the porcine 




then observed with a confocal laser scanning microscope. The bright field 
image was used to identify the upper surface of the bladder in Figure 3.13a1. 
At the same spot, green fluorescent dots were observed on the upper surface of 
the bladder (Figure 3.13a2). In contrast, after incubation with PBS, a much 
weaker green background arising from auto-fluorescence of the bladder can be 
observed (Figure 3.13b2). In addition, alcian blue staining was used to identify 
the GAG layer on the upper surface of the bladder urothelium, and a 
fluorescence microscope was applied to observe the alcian blue-stained 
urothelium treated with FITC-PAm-NH2 or PBS. Figure 3.14(a, c) clearly 
shows the blue-stained mucin layer on the surface of the urothelium. For the 
alcian blue-stained and FITC-PAm-NH2-treated urothelium, green 
fluorescence can be observed at the same spot (Figure 3.14d). For the 
unstained and FITC-PAm-NH2-treated urothelium, no blue color was observed 
(Figure 3.14e) but similar green fluorescence as the stained and FITC-PAm-
NH2-treated urothelium was present. These results indicate that FITC-PAm-






Figure 3.13. Cross-section view CLSM images of fresh porcine bladder 
urothelium after incubation for 4 h with 5 mg/ml FITC-PAm-NH2 nanogels (a) 
or PBS as control (b) under bright field (a1, b1) or FITC (a2, b2) filter. In (a2, 
b2), the xz and yz section views are also shown and the inset (top right) is the 
yz section view of (a2) at a higher magnification. The arrow indicates the 
direction towards the inner part of the urothelium. (c) Plot of mean intensity of 
the fluorescence per unit area against the depth into porcine bladder 
urothelium. (d) Plot of integrated fluorescence intensity throughout the CLSM 
scanned volume of the bladder urothelium after incubation with 5 mg/ml and 1 
mg/ml FITC-PAm-NH2 nanogels or PBS for 4 h. Data shown is the average of 





Figure 3.14. Fluorescence microscopy images (bright field and FITC channel) 
of alcian blue-stained fresh porcine bladder urothelium after incubation for 4 h 
with PBS (a, b) or 5 mg/ml FITC-PAm-NH2 nanogels (c, d). Unstained 
bladder urothelium (e, f) is also shown after incubation with 5 mg/ml FITC-
PAm-NH2 nanogels.  
 
The xz and yz cross-section view images along the x- and y-axis in Figure 
3.13a2 and 3.12b2 also illustrate the difference in fluorescence intensity and 
thickness between the bladder pieces after treatment with FITC-PAm-NH2 




axis is shown in Figure 3.13c. It can be seen that after incubation with 5 
mg/ml FITC-PAm-NH2, fluorescence due to the nanogels was detected to a 
depth of ~80 μm from the outer surface of the urothelium. In Figure 3.13a2, 
the yz cross-section image at a higher magnification shows the thickness of the 
fluorescent nanogel-covered layer. It has been reported that the GAG layer on 
the urothelium surface is about 30~50 μm in thickness (Anand et al., 2012, 
Birder and Andersson, 2013). The similarity between the depth of the 
fluorescence signal and the GAG layer thickness indicates that the fluorescent 
nanogels mainly interacted with and are attached on the GAG layer. In 
addition, quantification of fluorescence intensity was also carried out by 
integrating the intensity throughout the whole volume scanned by CLSM at a 
fixed magnification for a fixed area of 1.62×106 μm2. As shown in Figure 
3.13d, the integrated fluorescence intensity indicated concentration-dependent 
mucoadhesivity of FITC-PAm-NH2 on the bladder urothelium. 
3.3.7  Effect of PAm-NH2 on the Morphology of the Urothelium 
The permeability of the urothelium is very low to prevent substances in the 
urine from contacting the bloodstream. The uroplakin-covered umbrella cells 
and the mucin layer comprising GAGs on the top of the urothelium contribute 
to the so-called bladder permeability barrier (BPB). An IDD system has to 
overcome the BPB and enhance the penetration of the desired drug into the 
bladder urothelium. In the above sections, the mucin-particle method and ex 
vivo experiment have been applied to show that PAm-NH2 nanogels are able 




morphology of urothelium has been reported to be affected by some 
mucoadhesive polymers (Kos et al., 2006, Veranic et al., 2009), and this effect 
may increase the transport of drugs across the urothelium (Kerec Kos et al., 
2009, Kos et al., 2006). 
 
Figure 3.15. SEM images of the morphology of the fresh porcine bladder 
urothelium after exposure to PBS (a, b), 5 mg/ml NA-PAm dispersion (c), 5 mg/ml 
PAm-NH2 dispersion (d), 0.2 mg/ml (e) or 1 mg/ml (f) chitosan solution (positive 




Scanning electron microscopy was used to investigate the effect of PAm-NH2 
nanogels on the urothelium morphology. As SEM is a common dry technique 
for examining the morphology of biological tissues at high resolution, some 
distortion of the sample may result during its preparation for the analysis. To 
maximally preserve the original form and structure, dehydration of samples by 
freeze-drying and chemical fixation must be conducted. Figure 3.15a shows 
the SEM image at low magnification of the bladder urothelium exposed to 
PBS for 4 h. The bladder urothelium surface appeared to be intact although 
wrinkled due to the fixation process. At higher magnification, the urothelium 
in Figure 3.15b appeared smooth because of the mucin layer and uroplakin-
covered superficial umbrella cells. After exposure to NA-PAm solution (5 
mg/ml), the bladder inner surfaces in Figure 3.15c also appeared intact and 
smooth. However, treatment with 5 mg/ml PAm-NH2 nanogels resulted in 
some pits and cracks on the surface of the bladder urothelium (indicated by 
red ovals in Figure 3.15d) and the surface also appeared more wrinkled. These 
changes may be a sign of initial stages of exfoliation of the urothelium. A 
positive control was also conducted using CS, a well-investigated 
mucoadhesive polymer. The bladder wall after exposure to 0.2 mg/ml CS 
solution exhibited a less intact surface with evidence of exfoliation of the 
urothelium and appearance of the intermediate cells (Figure 3.15e), which are 
located under the umbrella cells (Kos et al., 2006, Tyagi et al., 2006). 
Furthermore, treatment with 1 mg/ml CS solution results in extensive damage 
of the urothelium with complete removal of the umbrella cells (Figure 3.15f). 




led to the complete removal of the superficial layer of cells within 20 min 
(Veranic et al., 2009). This is in line with the results of our positive control. 
Therefore, it can be concluded that the bladder urothelium is much more 
tolerable to PAm-NH2 compared with CS at even lower concentration. The 
mucoadhesivity of PAm-NH2 and its effect on the bladder urothelium are 






A positively charged nanogel (PAm-NH2) as potential hydrophobic drug 
carrier for treatment of NIMBCs was synthesized via copolymerization of 
amine group-containing monomers. An ex vivo model using porcine bladder 
tissue confirmed the mucoadhesivity of the PAm-NH2 nanogel which attached 
readily onto the bladder luminal surface to a depth of ~80 μm, and yet did not 
cause significant disruption of the urothelium. The uptake of the nanogels by 
both UMUC3 and T24 cells was demonstrated in a concentration-dependent 
manner at concentrations between 0.05-1 mg/ml. Endocytosis of the FITC-
PAm-NH2 nanogels by the UMUC3 cells was confirmed using a pulse/chase 
protocol. DTX was successfully loaded into nanogels and constituted ~5 wt% 
of the nanogel. 75% of the loaded DTX was released in a sustained manner in 
artificial urine over 9 days. The in vitro killing efficacy of DTX loaded in 
PAm-NH2 was found to be similar to free DTX for both T24 and UMUC3 
bladder cancer cells, with UMUC3 cells being more sensitive to the 
formulation than T24 cells. The results obtained indicate that the PAm-NH2 
nanogel has a number of advantages for site-specific delivery of hydrophobic 













CHAPTER 4 MUCOADHESIVE NANOCAPSULE AS 
A DUAL DRUG CARRIER WITH HIGH LOADING 
AND SYNERGISTIC EFFECTS AGAINST NON-
MUSCLE-INVASIVE BLADDER CANCER 
 
 




The PAm-NH2 nanogel reported in Chapter 3 is capable of loading 
hydrophobic drug, but its loading capacity is low (only 5%) and its ability to 
co-deliver two types of anti-cancer drugs in one formulation to NMIBCs is 
limited. Hence, in this Chapter, the development of another soft material, the 
nanocapsule, as a dual drug carrier with high drug loading for potential 
synergistic intravesical chemotherapy of NMIBCs is described. Synergism 
through combination chemotherapy offers the advantage of increased 
therapeutic efficacy, and a promising way to overcome adverse side effects 
and drug resistance. Combination of Dox with CDDP in a Phase III trial has 
shown enhanced therapeutic effect on endometrial carcinoma (Thigpen et al., 
2004). Recently, co-instillation of two or more drugs has shown potentiality 
for intravesical chemotherapy against NMIBCs (Breyer et al., 2010, Chen et 
al., 2012). A cocktail regimen involving sequential weekly intravesical 
mitomycin-C, Dox, and CDDP has been reported to reduce the recurrent rate 
in patients with NMIBCs (Chen et al., 2012). At present, hydrophilic drugs 
such as mitomycin-C, Dox, and CDDP are mainly used for intravesical 
instillation due to their high solubility. However, their low penetration and 
short residence time lead to low drug concentration at tumor site and thus low 
therapeutic effect even with high dosage, especially for CDDP (Delto et al., 
2013). 
Nanocapsules, which have a typical hollow core-shell structure with 
chemotherapeutic agents confined to the cavity and protected by a polymer 
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coating, are considered promising drug carriers (Mora-Huertas et al., 2010). 
Due to their unique structure, nanocapsules are reported to generally possess 
high loading capacity and provide sustained release (Torchilin, 2006) (as 
described in Section 2.1.3). 
In this study, CS-polymethacrylic acid nanocapsules (CM) were prepared via 
polyelectrolyte interaction of CS and polymethacrylic acid (PMAA) during the 
polymerization of methacrylic acid. The nanocapsule was designed with a 
hollow core for loading the hydrophobic form of Dox (obtained via 
neutralization of Dox·HCl at pH 7~8), a shell of PMAA for trapping Nα-
acetyllysine-modified CDDP (Pt-ALy), and an outer layer of CS for 
mucoadhesion to the bladder urothelium. Although the -COOH group of 
PMAA is able to conjugate CDDP, the efficiency and capacity are low (Huang 
et al., 2012). To facilitate CDDP loading, Nα-acetyllysine (ALy), an amine-
terminated peptide, was conjugated to CDDP. Small molecules like Pt-ALy 
and Dox can be loaded into the nanocapsules either via diffusion through the 
shell into the hollow core or via electrostatic interaction with the shell to 
achieve high loading capacities. 
CS is a well-established mucoadhesive polysaccharide used as a drug carrier 
for enhancing the contact between drugs and bladder for better tissue 
permeability and longer residence time (Barthelmes et al., 2011, Smart, 2005, 
Takeuchi et al., 2001, van der Lubben et al., 2001, Wittaya-areekul et al., 
2006). However, there is evidence that instillation of CS solution may cause 
deterioration of the urothelium (Kos et al., 2006). Thus, the biocompatibility 
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of the nanocapsules and their ex vivo mucoadhesivity on the bladder 
urothelium were evaluated. The possibility of synergism from the co-delivery 
of a combination of Dox and Pt-ALy via nanocapsules to UMUC3 bladder 
cancer cells, as illustrated in Figure 4.1, was also investigated. 
 
Figure 4.1. Schematic diagram showing the preparation of CM nanocapsules 
via electrostatic interaction of chitoson (CS) and poly(methacrylic acid) 
(PMAA) during the polymerization of methacrylic acid (MAA), and the 
subsequent loading of dual drugs: Dox and Pt-ALy. The electrostatic 
interaction between PMAA and CS in the shell of the CM nanocapsules, and 
intravesical co-delivery of Dox and Pt-ALy to the bladder urothelium via the 
mucoadhesive CM nanocapsules are also shown. 
 
4.2 Materials and Methods 
4.2.1  Materials 
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Doxorubicin hydrochloride (Dox·HCl) was purchased from LC Labs (Woburn, 
MA). Methacrylic acid (MAA), chitosan (CS, deacetylation degree ≥75%), 
silver nitrate, cisplatin (CDDP), sodium hydroxide, and Nα-acetyllysine (ALy) 
were purchased from Sigma-Aldrich (St. Louis, MO). All other solvents and 
chemicals were similar to those described in Section 3.2.1.  
4.2.2  Preparation of Chitosan-Polymethacrylic Acid (CM) 
Nanocapsules 
Chitosan-polymethacrylic acid (CM) nanocapsules were prepared via 
electrostatic interactions between chitosan and methacrylic acid (MAA) chains 
undergoing polymerization, according to an earlier reported method with some 
modifications (Hu et al., 2004). Briefly, 0.20 g of CS was dissolved in 20 ml 
of MAA solution (4.4 mg/ml) with magnetic stirring. The resulting solution 
was sonicated to ensure saturation with CS. After that, the solution was 
vacuum-filtered to remove any excess CS particles. The filtrate was degassed 
by bubbling argon through it for 2 h with magnetic stirring. Subsequently, 
polymerization of MAA was initiated by adding 40wt% APS solution (0.5 ml) 
to the solution at 70 ºC under argon. The polymerization was completed in 2 h 
and an opalescent suspension was obtained. The sample was purified via 
dialysis against deionized (DI) water (pH = 4.5) for 3 days using a membrane 
dialysis bag (molecular weight cutoff (MWCO) of 12400 Da, Sigma). The CM 
nanocapsules were then diluted to 5 mg/ml in DI water for subsequent use. 
FITC-labeled CM nanocapsules (FITC-CM) were prepared as follows: 0.2 
mg/ml of FITC in 0.5 ml methanol was added into 10 ml of as-prepared CM 
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nanocapsules suspension and the reaction mixture was kept in the dark for 24 
h at room temperature. The FITC-CM sample was then separated by 
centrifugation and washed with 50 ml DI water three times to remove the free 
and unreacted FITC. 
4.2.3  Synthesis of Nα-acetyllysine-modified CDDP (Pt-ALy) 
Peptide-modified CDDP, as a Pt prodrug, was synthesized via the conjugation 
of Nα-acetyllysine to [Pt(NH3)2]2+ of CDDP, according to a procedure reported 
in the literature with some modifications (Appleton et al., 1989, Hadi and 
Appleton, 2010). Briefly, 60 mg of CDDP was dissolved in warm DI water in 
a round bottom flask with magnetic stirring. 68 mg of silver nitrate was added 
into the resulting solution at stoichiometric ratio (i.e. equimolar ratio of 
AgNO3 to Cl- in CDDP). Then, the solution was incubated in the dark for 3 
days at room temperature with magnetic stirring. After that, the solution was 
stored at 4 ºC overnight to allow complete precipitation of silver chloride. To 
check for completion of the reaction and all the silver has been precipitated, a 
small amount of the reaction mixture was removed and added to sodium 
chloride. Subsequently, the silver chloride precipitate was removed via 
centrifugation at 9000 rpm for 20 mins, followed by passage through a syringe 
filter (pore size of 0.2 μm). Next, 37.6 mg of Nα-acetyllysine was added, and 
the pH was adjusted to ~5 with 100 mM NaOH solution and maintained for 48 
hours at 50 ºC in the dark. The reaction progress can be monitored by 
checking the pH of the solution as the generation of protons will decrease the 
pH to below 3. Finally, the yellowish-white solution was concentrated and 
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transferred to a refrigerator and kept overnight, during which time a white 
solid precipitated out. The white Nα-acetyllysine-modified CDDP solid (Pt-
ALy) was washed with cold water and collected. The success of synthesis of 
Pt-ALy with the structure of cis-[Pt(NH3)2(Nα-acetyllysine)] was confirmed 
using micrOTOF-Q electrospray ionization mass spectrometry (ESI-MS, 
Bruker, Billerica, MA) in negative ion mode. 
4.2.4  Loading of Dox, CDDP and Pt-ALy into CM Nanocapsules 
Dox, one of the most common pH-sensitive drugs, has been used as an 
anticancer agent against bladder cancers. To load Dox into CM nanocapsules, 
predetermined amounts of Dox·HCl and nanocapsules (mass ratios of 
Dox·HCl:nanocapsules of 1:3 and 3:3) in DI water were transferred to a round 
bottom flask. The pH of the mixture was adjusted to 7~8 using 100 mM 
NaOH solution to convert Dox·HCl to a hydrophobic form (Li et al., 2013, 
Sanson et al., 2010), which can be trapped and stabilized in the CM 
nanocapsules. The mixture was then incubated under magnetic stirring in the 
dark overnight. The Dox-loaded CM nanocapsules (CM-Dox1 and CM-Dox2) 
were centrifuged (9000 rpm, 10 mins) and washed three times with DI water. 
Using the same method, Dox-loaded FITC-CM nanocapsules (FITC-CM-Dox) 
were prepared at a feed ratio of Dox·HCl:FITC-CM of 1:3. The Dox loading 
was estimated using UV-vis absorption spectroscopy by subtracting the 
amount of Dox in the collected supernatant from the total amount of Dox 
added. A standard calibration of Dox·HCl at concentration ranging from 2 to 
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500 μg/ml in DI water (R2>0.99) was used for this purpose. Thus, the amounts 
of Dox in this study are expressed as equivalents of Dox·HCl on a mass basis. 
 CDDP and Pt-ALy, as hydrophilic anticancer agents, were also loaded into 
CM nanocapsules using a similar method as Dox loading. Briefly, Pt-ALy (or 
CDDP) and nanocapsules at predetermined mass ratios (1:3 to 3:3 for Pt-ALy 
and 1:20 to 1:2 for CDDP) in DI water were placed in a round bottom flask. 
NaOH solution (100 mM) was used to adjust the pH of the mixture to 7~8 to 
facilitate the electrostatic interactions between the amine groups of Pt-ALy 
with the carboxyl groups of CM nanocapsules. The mixture was then 
incubated under magnetic stirring in the dark overnight. The Pt-ALy- or 
CDDP-loaded CM nanocapsules (CM-PtALy1~CM-PtALy3 and CM-
CDDP1~CM-CDDP3, Table 4.1) were centrifuged (9000 rpm, 10 mins) and 
washed three times with DI water. The Pt loading was estimated using a 
HP7500a inductively coupled plasma mass spectrometer (ICP-MS, Agilent 
Technologies, Santa Clara, CA). Based on the feed ratio of Pt-ALy to 
nanocapsules which resulted in the highest loading capacity (definition given 
below) of Pt-ALy, the co-loading of Dox and Pt-ALy into CM nanocapsules 
(CM-Dox-PtALy) was carried out with Dox·HCl:Pt-ALy:nanocapsules at a 
mass ratio of 1:2:3 using the same method. 
The loading efficiency and capacity of the drug-loaded formulations are 
summarized in Table 4.1. The loading efficiency is defined as the percentage 
of the initial amount of drug that is loaded in the nanocapsules, whereas the 
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loading capacity is defined as the weight of the loaded drug normalized by the 
initial amount of nanocapsules. 
Table 4.1. Loading efficiency and capacity of Dox, CDDP, Pt-ALy in CM 
nanocapsules at various mass feed ratios. 
Sample 







CM-Dox1a 1:3 92.9±0.2 31.6±0.1 
CM-Dox2a 3:3 95.2±0.1 95.2±0.1 
CM-CDDP1b 1:20 2.1±0.1 <0.5 
CM-CDDP2b 1:10 2.3±0.1 <0.5 
CM-CDDP3b 1:2 1.4±0.1 0.7±0.1 
CM-PtALy1b 1:3 68.3±4.2 22.8±1.4 
CM-PtALy2b 2:3 47.3±0.8 31.5±0.5 
CM-PtALy3b 3:3 31.3±0.7 31.3±0.7 
CM-Dox-PtALya,b 1(Dox):2(Pt-ALy):3 81.1±0.3a/35.2±1.6b 27.0±0.1a/23.5±1.1b 
a amount of Dox was determined using UV-vis absorption spectroscopy; b amount of 
Pt was determined using ICP-MS.  
 
4.2.5 Characterization of Blank, Dox- and Pt-ALy-loaded CM 
Nanocapsules 
Zeta potential of the CM nanocapsules dispersed in water was determined 
using a zeta-sizer nanosystem as described in Section 3.2.4. The morphology 
and size of blank and drug-loaded CM nanocapsules (CM-Dox-PtALy) were 
observed on a Nanoscope IIIa atomic force microscope (AFM, Digital 
Instrument Inc., Tonawanda, New York) and a JSM-6700 field emission 
scanning electron microscope (FESEM, JEOL, Tokyo, Japan) at an 
accelerating voltage of 5 kV. The specimens for FESEM were prepared by 
depositing a drop of a dilute aqueous dispersion on a glass slip. The samples 
for AFM were prepared by depositing a drop of the aqueous dispersion on the 
glass slip and then using spin-coating to obtain a thin layer of nanocapsules, 
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followed by drying in air for one day. To determine the surface chemical 
composition of the blank and Pt-ALy-loaded CM nanocapsules, X-ray 
photoelectron spectroscopy (XPS) was carried out on an AXIS Ultra DLD 
spectrometer (Kratos Analytical Ltd, Manchester, UK) with a 
monochromatized Al Kα X-ray source (1486.6 eV photons). The pressure in 
the analysis chamber was maintained at 6.7 × 10-6 Pa or lower during each 
measurement. The constant dwell time was fixed at 100 ms and the pass 
energy was maintained at 40 eV. The core-level signals were obtained at a 
photoelectron take-off angle of 90º with respect to the sample surface. Due to 
surface charging effect, the C 1s hydrocarbon peak at 284.6 eV was used as a 
reference for the binding energies (BEs) of the observed peaks. 
4.2.6  Evaluation of Mucoadhesivity of CM Nanocapsules via Mucin-
particle Method 
Mucin-particle method was applied to investigate the mucoadhesive properties 
of the CM nanocapsules (Huang et al., 2012, Thongborisute and Takeuchi, 
2008), as described in Section 3.2.5 with minor modifications. Mucin was first 
suspended in DI water (10 mg/ml) and incubated overnight at 37 ºC. The 
suspension was then sonicated for 30 min with a probe sonicator. After 
centrifugation at 4000 rpm for 30 min, the supernatant with mucin particles of 
~200 nm was collected. Subsequently, an equal volume of CM dispersion (2 
mg/ml) was mixed with the mucin suspension (1 and 5 mg/ml), followed by 
vortexing and incubation at 37 ºC for 30 min. The changes in turbidity of the 
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mixture were monitored by UV-vis spectroscopy at a wavelength of 600 nm. 
Each test was performed in triplicate. 
4.2.7  Determination of Dox and Pt-ALy Release from CM-Dox-PtALy 
Nanocapsules 
Drug release study was performed to determine the release profile of both Dox 
and Pt-ALy in a simulated bladder environment. In brief, a pre-determined 
volume of CM-Dox-PtALy suspension (prepared from 5 mg CM 
nanocapsules/ml), Dox, or Pt-ALy solution (with similar [Pt] or [Dox] as CM-
Dox-PtALy) was loaded into a dialysis bag (MWCO = 12 kDa). The dialysis 
bag was immersed into 10 ml of artificial urine (A.U.) or PBS at 37 ºC under 
constant shaking in a water bath shaker. At predetermined time intervals, 5.0 
ml of the dialysis medium outside dialysis bag was collected and replaced with 
5.0 ml of the respective medium to keep the volume constant at 10 ml. The 
amounts of Dox and Pt-ALy released into the collected medium were 
quantified using UV-vis absorption spectroscopy and ICP-MS, respectively. 
The data was expressed as cumulative percentage of drug released as a 
function of time. 
4.2.8  Cell Culture 
UMUC3 cells were cultured as described in Section 3.2.7. 
4.2.9  In vitro Killing Efficacy of UMUC3 by Single/Dual Drug-loaded 
Nanocapsules  
To determine the in vitro killing efficacy of single/dual drug loaded 
nanocapsules (CM-Dox1, CM-PtALy2, and CM-Dox-PtALy), MTT assay 
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with minor modifications was carried out to determine the viability of 
UMUC3 cells after treatment with these nanocapsules in DMEM medium. 
UMUC3 cells in 100 μl medium (5000/well) were seeded in each well in a 96-
well plate. After 24 h-incubation, the medium was aspirated from each well 
and replaced by 100 μl of fresh medium containing drug/nanocapsule 
formulations of various concentrations for either 4 h or 72 h. For the 4 h-
treatment, the medium containing the drug/nanocapsule formulation was 
removed after 4 h and the cells were further cultured for 72 h in fresh medium. 
After that, the MTT assay was carried out as described in Section 3.2.8. The 
results were expressed as percentages relative to the optical absorbance 
obtained from the control experiments which were carried out using culture 
medium without drugs and nanocapsules. The killing efficacies of free Dox, 
Pt-ALy and their combination were also determined by the same method and 
compared with that of the Dox and Pt-ALy combination in the nanocapsule 
formulation to evaluate possible synergistic effects of the latter. In addition, 
the cytotoxicity of blank CM nanocapsules at a concentration ranging from 
0.02 to 0.5 mg/ml was evaluated after 72 h-incubation.  
The possibility of synergism from the dual drug combination was evaluated 
using the Chou and Talalay method (Chou, 2010, 2006). The combination 
index (CI) is defined as the sum of the ratios of the dose (Dc1, Dc2) of each 
drug in the combination to the dose (D1, D2) of each drug alone at a certain 
fraction of affected cells (Fa): , and the dose-reduction 
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index (DRI) is defined as: . A value of CI close to 1 
indicates additive effect, while CI<1 and CI>1 indicate synergism and 
antagonism, respectively. The CI, DRI values and the half-maximal inhibitory 
concentrations (IC50) of Dox and Pt-ALy in free or nanocapsule formulations 
were analyzed at different Fa using CompuSyn software (Version 1.0, Combo-
Syn Inc., Paramus, NJ) and the median effect equation, 
, where D is drug concentration and m is the Hill 
slope (Chou, 1976, Zhao et al., 2004). The IC50 of the individual component 
was calculated from the IC50 of the drug combination, based on the loading of 
Dox and Pt-ALy in that formulation. 
4.2.10  Single- or Co-delivery of Dox and Pt-ALy via CM Nanocapsules 
To visualize the cellular uptake of free Dox and FITC-CM-Dox by UMUC3, 
5×105 cells per well were seeded in 6-well plates containing a cover slip on 
the bottom of each well. After incubation for 24 h, the cells were exposed to 
fresh medium containing either PBS, free Dox (2.45 mg/ml), or FITC-CM-
Dox (2.45 mg Dox/ml). After 4 h incubation at 37 ºC, the cells were washed 
three times with PBS (pH 7.4) to remove the free drug/nanocapsules, followed 
by cell fixation with 4% formaldehyde for 30 min. After washing with PBS, 
the cells on the cover slip were stained with 4’,6-diamidino-2-phenylindole 
(DAPI, 1 μg/ml) for 15 min, transferred to a glass slide, and viewed using a 
confocal laser scanning microscope (CLSM: Olympus FV1000, Tokyo, Japan). 
To investigate the cellular uptake of Dox and CM-Dox1, UMUC3 cells were 
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seeded in 6-well plates at a density of 5×105 cells per well for 24 h incubation 
and then treated with Dox (2.45 and 24.5 mg/ml) or CM-Dox1 (2.45 mg, 12.3 
mg, and 24.5 mg Dox/ml). After 4 h-incubation, the cells were washed three 
times with PBS, trypsinized and then analyzed by flow cytometry (FACScan, 
Becton Dickinson, Franklin Lake, NJ) with acquisition of fluorescence 
emission at 575 nm. The histogram of each sample was obtained by counting 
10,000 events. 
To quantify the cellular uptake of Pt-ALy, UMUC3 cells were seeded in 6-
well plates at a density of 5×105 cells per well and allowed to grow for 24 h. 
The cells were then cultured with fresh medium containing either PBS, Pt-
ALy, CM-PtALy2 or CM-Dox-PtALy at the desired concentration (1 μg Pt/ml 
for all formulations except for PBS) for 4 h. After washing three times with 
PBS, the cells were harvested by trypsinization, counted with a 
hemocytometer and collected by centrifugation. The cell pellets were 
dissolved in aqua regia solution (0.4 ml) and disrupted by sonication for 20 
min at 0 ºC prior to dilution with DI water to 1.5 ml. The cellular 
concentration of Pt ions (denoted as Pt-uptake in subsequent discussions) was 
determined using ICP-MS.  
4.2.11  Apoptosis Assay 
For apoptosis assay, Pt-ALy, CM-PtALy2 or CM-Dox-PtALy was used at a 
concentration of 0.1 μg Pt/ml for all formulations. Treatment of the cells with 
the formulation for 4 h and 72 h was carried out in a similar manner as the 
killing efficacy assay described above, except that the density of UMUC3 was 
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2×105 cells/well for the apoptosis assay. Flow cytometry was used to analyze 
the cells after staining with Annexin Alexa Fluor® 488 Annexin V/Dead Cell 
Apoptosis Kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. Cells in late apoptotic stages were labeled with both Annexin V-
Alexa Fluor 488 and propidium iodide. Early apoptotic cells with exposed 
phosphatidylserine but intact cell membranes bound to Annexin V-Alexa 
Fluor 488 but excluded propidium iodide, while necrotic cells were 
exclusively stained by propidium iodide rather than Annexin V-Alexa Fluor 
488 (Bachleitner-Hofmann et al., 2011, Fabre et al., 2012). 
4.2.12  Ex vivo Mucoadhesivity and Bladder Morphology Study 
An ex vivo model based on freshly excised porcine urinary bladders on a 
customized well-plate setup was used to evaluated the mucoadhesivity of 
FITC-labelled CM nanocapsules (FITC-CM) at 5 mg/ml in A.U., as described 
in Section 3.2.10. The effect of the CM nanocapsules in A.U. on the bladder 
urothelium morphology was also studied as described in Section 3.2.11. The 
experiment was repeated with 1 mg/ml CS (with 0.01% acetic acid) in A.U. as 
the positive control.  
4.2.13  Statistical Analysis 
At each experimental condition, three runs were carried out and the results 
were expressed as mean±standard deviation. Statistical analysis was 
conducted using one-way analysis of variance (ANOVA). 
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4.3 Results and Discussion 
4.3.1  Preparation and Characterization of CM Nanocapsules 
The CM nanocapsules were prepared via electrostatic interaction of chitosan 
(CS) and poly(methacrylic acid) (PMAA) during the polymerization of 
methacrylic acid. Although CS is insoluble in DI water, it can be dissolved in 
MAA solution due to protonation of CS in an acidic environment. The initially 
clear solution became colloidal after polymerization, which suggests that 
particles were formed. The formation of colloids is postulated to be due to the 
formation of a polyelectrolyte complex between the COO- groups of PMAA 
and the amine groups of CS, as illustrated in Figure 4.1. The zeta potential of 
these CM nanocapsules is about +15 mV (Figure 4.2a), suggesting that the 
outermost layer of the nanocapsules is predominantly CS with protonated 
amine groups. This is advantageous for intravesical therapy due to the 
mucoadhesive property of CS. The XPS results of CM nanocapsules are 
shown in Figure 4.3. The C 1s core-level spectrum of CS (Figure 4.3b) can be 
curve-fitted into four component peaks with BEs at 284.6 eV for the C-C/C-H 
species, 285.6 eV for the C-N species, 286.1 eV for the C-O species, and 
287.8 eV for N-C=O/O-C-O species (Xu et al., 2009). The C 1s core-level 
spectrum of CM nanocapsules (Figure 4.3d) can be curve-fitted into five peak 
components with BEs at 284.6, 285.6 eV, 286.1, 287.8, and 288.7 eV, 
attributable to the C-C/C-H, C-N, C-O, N-C=O/O-C-O and O-C=O species, 
respectively (Yang et al., 2013). The [C-N]:[N-C=O/O-C-O] peak component 
area ratio is about 1:1.6, in agreement with that of CS, which is as expected 
since these components are only present in CS. For the CM nanocapsules, the 
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increase in the peak intensity of the C-C/C-H species relative to the C-O 
species as compared to CS, and the appearance of a peak attributed to the O-
C=O species at 288.7 eV confirm that the CM nanocapsules comprises PMAA 
as well as CS.  
 
Figure 4.2. Zeta potential (a) and SEM images (b) of CM nanocapsules. 




Figure 4.3. XPS wide scan (a, c, e), C 1s core-level spectra (b, d) of CS, and 
CM nanocapsules and Pt 4f core-level spectra (f) of CM-PtALy2. 
 
The size of these CM nanocapsules was estimated to be 50~100 nm from the 
SEM image (Figure 4.2b), which is consistent with an earlier report (Hu et al., 
2004). AFM was also used to get more information on the morphology of the 
CM nanocapsules. The AFM images showed that these CM nanocapsules have 
a donut-like appearance (Figure 4.4a) with diameter of ~200 nm, which is 
larger than the size observed from the SEM image (Figure 4.2b). The SEM 
and AFM images indicate that these spheres may have a hollow core which 
collapsed during spin coating of the soft particles and subsequent evaporation 
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of the solvent in the preparation of the samples for AFM evaluation. The CM 
nanocapsules possess potential advantages for IDD due to their nano size and 
positive charge which endow the capsules with a large specific surface area 
and mucoadhesiveness for attachment onto the urothelium. Furthermore, the 
hollow structure and polyelectrolyte nature allow for the loading of different 
anti-cancer drugs with high capacity and efficiency. 
 
Figure 4.4. AFM images of blank CM nanocapsules (a) and drug-loaded CM 
nanocapsules (CM-Dox-PtALy) (b). 
 
The mucoadhesivity of the CM nanocapsules was evaluated using the mucin-
particle method (Huang et al., 2012, Thongborisute and Takeuchi, 2008) with 
some modifications. The turbidity of a suspension with 1 mg/ml or 5 mg/ml of 
mucin was monitored after incubation with an equal volume of nanocapsule 
dispersion (2 mg/ml). The turbidity of the suspension provides an indication of 
the interaction between mucin particles and the nanocapsules. As shown in 
Figure 4.5, the turbidity of 1 mg/ml mucin suspension after mixing with 2 
mg/ml CM nanocapsules increased significantly from 0.04 to 0.27. When 
mucin suspension of 5 mg/ml was mixed with the same amount of CM 
nanocapsules (2 mg/ml), the turbidity further increased to 0.53. It should be 
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noted that these turbidity readings are also much higher than that obtained 
with 1 mg/ml CM nanocapsules alone (0.1). It can be deduced that with 
increasing mucin concentration, interactions between mucin and CM 
nanocapsules increased, which resulted in larger aggregates and hence higher 
turbidity of the suspension. This mucoadhesive behavior is likely due to the 
electrostatic interaction between the positively charged CS on the surface of 
the nanocapsules and the negatively charged mucin.  
 
Figure 4.5. Mucoadhesive property of CM nanocapsules as indicated by the 
change in turbidity after mixing CM dispersion (2 mg/ml) with equal volume 
of 1 mg/ml (CM+Mucin1) and 5 mg/ml (CM+Mucin5) mucin suspension. 
Mucin suspension (Mucin, 0.5 mg/ml) and CM dispersion (CM, 1 mg/ml) 
were used as control. 
 
4.3.2  Loading of Dox and Cisplatin Drugs into CM Nanocapsules.  
Dox and Pt-ALy were loaded into the CM nanocapsules via a simple method 
based on electrostatic interaction as shown schematically in Figure 4.1. In 
Table 4.1, it can be seen that Dox was loaded into CM nanocapsules with very 
high loading efficiency (>90%) at Dox to nanocapsules feed ratio of 1:3 and 
3:3 (CM-Dox1 and CM-Dox2). The loading capacity of Dox in CM 
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nanocapsules can thus reach as high as 95.2±0.09% (CM-Dox2). This is 
attributed to the interactions between the amine groups of Dox with the 
carboxyl groups of PMAA in the nanocapsules as well as the availability of 
space within the nanocapsules to accommodate the hydrophobic form of Dox 
at pH 7~8. Poly(acrylic acid) nanoparticles with similar hollow core as 
nanocapsules, and porous shell structure that have a high loading efficiency 
(e.g. ~90% for Dox loading) and a super-high capacity of drug loading (e.g. 
169% for Dox loading) have been reported (Chen et al., 2010), which is 
consistent with our results. On the contrary, hardly any CDDP was loaded into 
the CM nanocapsules. The amount of Pt loaded was only 0.7wt% of the 
nanocapsules and the loading efficiency was 1.3%. CDDP is a neutral and 
water-soluble molecule, and hence there is minimal interaction between the 
CM nanocapsules and CDDP. 
In order to increase CDDP loading in the CM nanocapsules, peptide-modified 
CDDP, cis-[PtII(NH3)2(Nα-ALy)] (Pt-ALy), was prepared (Appleton et al., 
1989, Hadi and Appleton, 2010). The structure of Pt-ALy was confirmed by 
ESI-MS (Figure 4.6a). The isotope distribution of one set of peaks at m/z of 
~416 matches the theoretical isotope distribution of [cis-[Pt(NH3)2(Nα-
ALy)]+H]+ (singly charged ion, m/z 416.1), which confirms the molecular 
formula of the prepared product (Pt-ALy). The maximum loading capacity of 
Pt-ALy in the CM nanocapsules is around 31% (CM-PtALy2 and CM-
PtALy3), which is much higher than that of the CDDP-loaded nanocapsules. 
The high loading capacity can be attributed to the amine group of ALy, which 
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interacted electrostatically with the carboxyl group of PMAA of the 
nanocapsule when it was loaded at pH 7~8. The loading efficiency decreases 
when the feed ratio of Pt-ALy to nanocapsules increased from 1:3 to 3:3. Thus, 
CM-PtALy2 was selected for the drug delivery and efficacy against bladder 
cancer cells experiments. The encapsulation of Pt-ALy in the nanocapsules 
was confirmed by XPS. The wide scan spectrum of CM-PtALy2 in Figure 
4.3e shows a peak around 75 eV attributed to Pt 4f, which was absent in the 
spectrum of blank CM nanocapsules (Figure 4.3c). In the Pt 4f core-level XPS 
spectrum of CM-PtALy2, the Pt 4f5/2 and Pt 4f7/2 peaks were observed at BEs 
of 73.2 and 76.5 eV, respectively (Figure 4.3f), similar to the spectrum of Pt-
ALy (Figure 4.6b). 
 
Figure 4.6. (a) ESI-MS isotopic pattern and (b) XPS Pt 4f core-level spectra 
of Pt-ALy. 
 
Combined loading of Dox and Pt-ALy into CM nanocapsules was conducted 
with a Dox/Pt-ALy/CM nanocapsules feed ratio of 1:2:3. The Dox-loading 
capacity and Pt-ALy-loading capacity of CM-Dox-PtALy are 27.0±0.1% and 
23.5±1.1%, respectively, slightly lower than that of single drug-loaded 
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nanocapsules (CM-Dox1 and CM-PtALy2) at the same feed ratio. The 
morphology of the dual drug-loaded nanocapsules (CM-Dox-PtALy) was 
investigated using AFM (Figure 4.4b). The CM-Dox-PtALy nanocapsules do 
not exhibit a hollow structure, unlike the blank CM nanocapsules (Figure 4.4a). 
This may be attributed to the high loading of the drugs inside the hollow core 
(constituting ~50 wt% of the weight of the initial nanocapsules), which 
provides support for the soft shell.  
4.3.3  Dox and Pt Release from CM-Dox-PtALy Nanocapsules 
For intravesical treatment of NIMBCs, drugs loaded into carriers must be able 
to diffuse out to achieve the desired chemotherapeutic effect. However, an 
immediate and complete release of the drugs from the carriers after instillation 
in the bladder is not desirable as most of drugs will be lost upon first urine 
voiding after instillation. On the other hand, a very slow drug release is also 
undesirable as the local drug concentration will be too low to achieve any 
substantial therapeutic effect.  
The release of Dox and Pt-ALy from CM-Dox-PtALy nanocapsules was 
evaluated using dialysis at 37 ºC against PBS (pH 7.4) and A.U. (pH 6.1), to 
simulate a bladder environment. Figure 4.7 shows that both Dox and Pt-ALy 
were released at a faster rate at pH 6.1 than pH 7.4, indicating pH-sensitive 
release property. The release profiles of Dox and Pt-ALy started with a rapid 
release phase in the first 7 h and continued with a slow release phase over 3 
days in either medium. In the case of Pt release, 32% of the Pt-ALy (Figure 
4.7a) was released from CM nanocapsules by 7 h and 44% after 3 days in A.U., 
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while the corresponding release was 13% and 22% in PBS. Similarly for Dox, 
in A.U., 44% and 56% (Figure 4.7b) was released from the CM nanocapsules 
after 7 h and 3 days, respectively, compared with 22% and 30% in PBS. 
Incomplete release of Dox is commonly observed when the pH of the dialysis 
medium is higher than 6 (Dong et al., 2015, Kim et al., 2008). This is 
probably because Dox has low solubility and its solution has high viscosity at 
higher pH (Fritze et al., 2006). Thus, a certain amount of the drug may 
strongly attach into the carrier matrix and onto the dialysis membrane. In 
contrast to drug-loaded nanocapsules, 60-80% of Pt-ALy and Dox diffused out 
rapidly from the dialysis bag when the free form of the drug was dialyzed 
against A.U. or PBS for 5 h. These results demonstrate that CM-Dox-PtALy 
can effectively unload its cargoes in the bladder environment with a sustained 
release profile, which would be advantageous for intravesical bladder cancer 
chemotherapy.  
Figure 4.7. Cumulative Pt (a) and Dox (b) release from dual drug-loaded 
nanocapsules (CM-Dox-PtALy) in A.U. or PBS at 37 ºC. Control experiments 
were also carried out with free Dox or Pt-ALy in the dialysis bag. 
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4.3.4 Killing Efficacy of Dox or PtALy Loaded in CM Nanocapsules  
The killing efficacy of the nanocapsules loaded with single drug, CM-Dox1 
and CM-PtALy2, was evaluated against UMUC3 human urothelial carcinoma 
cell line. The cells were exposed to the drug formulations for 4 h or 72 h to 
simulate current clinical instillation therapy or in vitro pharmaceutical test 
(Mugabe et al., 2011), respectively. The cell viability after treatment with the 
drug-loaded nanocapsules as determined by MTT assay is shown in Figure 
4.8. The corresponding half-maximal inhibitory concentrations (IC50(Dox) and 
IC50(Pt)) were calculated using the Chou and Talalay method and listed in 
Table 4.2 (Chou, 2006). In the case of Dox delivery, CM-Dox1 has a much 
higher IC50(Dox) than free Dox for both 4 h and 72 h treatment: 16 times for 4 
h-treatment and 7.5 times for 72 h-treatment.  
Table 4.2. Half-maximal inhibitory concentration (IC50(Pt), IC50(Dox)) for 







4 h 72 h 4 h 72 h 
CM-Dox-PtALy 0.09 0.02 0.21 0.06 
CM-PtALy2 0.48 0.40 -- -- 
Pt-ALy 1.46 0.48 -- -- 
Dox -- -- 0.09 0.04 
CM-Dox1 -- -- 1.36 0.30 
 
 




Figure 4.8. In vitro viability of high-grade human urothelial carcinoma cell 
line UMUM3 after exposure to (a, b) free drugs (Dox or Pt-ALy) and their 
combination or (c, d) drug-loaded CM nanocapsules (CM-Dox1, CM-PtALy2, 
or CM-Dox-PtALy) at different concentrations for 4 h (a, c) or 72 h (b, d). The 
cells after 4 h-treatment were further cultured for 72 h in fresh medium. 
Control experiments were carried out without nanocapsule or drugs. For 
combined drugs either in free form or nanocapsules, the amount of Dox and 
Pt-ALy in the combination is indicated by the respective x-axis. (e, f) 
Combination index (CI) vs Fa plots of CM-Dox-PtALy and free drug 
combinations against UMUC3 cells after treatment for 4 h (e) or 72 h (f). Data 
shown are representative of at least 3 independent experiments. 
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The cellular uptake of FITC-CM-Dox and free Dox was visualized by 
confocal microscopy. As shown in Figure 4.9a, the red fluorescence from free 
Dox is completely overlaid with the DAPI-stained nucleus, indicating that 
Dox taken in by the cells has already entered the nucleus within 4 h. In 
contrast, in the case of FITC-CM-Dox (Figure 4.9b), red fluorescence is 
partially located outside the DAPI-stained nucleus after 4 h, and when the red 
fluorescence is merged with the green fluorescence of FITC, yellow color is 
observed, corresponding to Dox inside the FITC-CM nanocapsules. The 
intensity profile along the line bisecting the UMUC3 cell treated with FITC-
CM-Dox (Figure 4.9e(i)) also indicates that the red and blue signals do not 
completely overlap with each other. Red and green fluorescence is also present 
in the DAPI-stained nucleus, suggesting that Dox-loaded CM nanocapsules 
are able to enter and deliver their cargoes in the nucleus. This finding is 
consistent with a previous report using similar particles loaded with gold 
nanoparticles (Hu et al., 2009). This result suggests that the CM nanocapsules 
were able to escape from the endosomes into the cytosol and nucleus. It is 
postulated that this endosomal escape is facilitated by the CS component of 
the CM nanocapsules since polycations, such as CS, are able to buffer the 
acidic pH of the endosome (Fang et al., 2001, Richard et al., 2013). Thus, 
after CS-based nanoparticles are taken in through endocytosis, the membrane 
of the endosome may be ruptured due to the proton sponge effect of CS, 
resulting in the release of the nanoparticles (Cho et al., 2003, Fang et al., 
2001). CLSM images of UMUC3 cells incubated with FITC-CM-Dox indicate 
higher delivery of Dox into the nucleus with increasing treatment time (Figure 
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4.9d). Flow cytometry analysis shows that cellular uptake of Dox is similar 
when the cells were treated with CM-Dox1 or free Dox at Dox concentration 
of 2.45 and 24.5 μg/ml (Figure 4.10). However, since Dox was released from 
Dox-loaded CM nanocapsules in a sustained manner (Figure 4.7), the amount 
of effective Dox in the nucleus of UMUC3 cells treated with CM-Dox1 is less 
than that achieved with free Dox at the same incubation time. Since Dox is a 
DNA-damaging agent which intercalates with DNA (Minotti et al., 2004), the 
difference in the amount of effective Dox delivered to the nucleus is likely to 
be the reason for the difference in the killing efficacy of free Dox and CM-
Dox1. 




Figure 4.9. CLSM images of UMUC3 cells after incubation in medium 
containing 2.45 μg/ml Dox either in free form (a) or in FITC-CM-Dox 
nanocapsules (b) for 4 h at 37 ºC. Control experiments were carried out with 
PBS (c). In (a), (b) and (c), the images show cell nuclei stained by DAPI 
(Blue), FITC (Green), Dox (Red), and an overlay image (Merged). (d) Merged 
CLSM images of FITC-CM-Dox (2.45 μg/ml Dox)-treated UMUC3 cells as a 
function of treatment time. (e) (i) Intensity profile of the fluorescent signals in 
the FITC-CM-Dox-treated cell along the white arrow in the merged image in 
(b), and (ii) intracellular Pt concentration after incubation of UMUC3 cells 
with Pt-ALy, CM-PtALy2, and CM-Dox-PtALy nanocapsules (with 
equivalent [Pt] of 1 μg/ml) for 4 h at 37 ºC. 





Figure 4.10. Flow cytometry histograms of UMUC3 cells treated for 4 h at 37 
ºC with (a) free Dox at a concentration of 2.45 and 24.5 μg/ml, and (b) CM-
Dox1 containing Dox at a concentration of 2.45, 12.3 and 24.5 μg/ml. The x-
axis gives the fluorescence intensity at 575 nm on a log10 scale, and the 
intensity of each sample is indicated. 
 
The killing efficacy of Pt-ALy and CM-PtALy2 are also shown in Figure 4.8. 
Interestingly, the IC50(Pt) of CM-PtALy2 for 4 h-treatment (0.48 μg/ml) is quite 
similar to that for 72 h-treatment (0.40 μg/ml) (Table 4.2). The apoptosis assay 
results (discussed in the following section) also show similar percentages of 
necrotic and apoptotic cells after treatment with CM-PtALy2 for 4 h and 72 h. 
This may be due to the rapid and efficient uptake (within 4 h) of the CM-
PtALy2 into the cells. After incubation of UMUC3 cells with CM-PtALy2 at 1 
μg/ml [Pt] for 4 h, the total Pt-uptake by the UMUC3 cells in a well was 0.33 
Chapter 4  
109 
 
μg, which is a relatively high amount considering the Pt in the CM-PtALy2 
dose was 1 μg/well. The intracellular Pt concentration was calculated to be 
0.27 pg/cell (Figure 4.9e(ii)). It should be noted that free Pt-ALy at the same 
Pt concentration resulted in extremely low cellular Pt-uptake (<0.003 pg/cell), 
nearly 100 times lower than that of CM-PtALy2. Thus, it is expected that 
treatment with CM-PtALy2 for 4 h would result in higher anticancer 
efficiency than the corresponding treatment with free Pt-ALy (Figure 4.8 and 
Table 4.2). However, it should be pointed out that the difference in killing 
efficiency between CM-PtALy2 and Pt-ALy (IC50 differs by a factor of 3) is 
not as high as the difference in cellular Pt-uptake. This is understandable since 
Pt-ALy would be only partially released from the CM-PtALy2 taken up by the 
UMUC3 cells within the 72 h incubation period after treatment as shown by 
Figure 4.7a. 
In the case of 72 h-treatment, the IC50(Pt) for free Pt-ALy has decreased by a 
factor of 3 compared to 4 h-treatment (to 0.48 μg/ml), whereas for CM-
PtALy2, treatment time did not change the IC50(Pt) substantially, as discussed 
above. This indicates that free Pt-ALy is not taken in as readily as CM-
PtALy2 by UMUC3 cells, and hence a longer treatment time is needed to kill 
the cells when free Pt-ALy is used. Thus, these results showed that by 
modifying CDDP to Pt-ALy, a Pt-containing prodrug can be loaded into the 
CM nanocapsules and subsequently delivered in an efficient manner to bladder 
cancer cells. Cytotoxicity assay with blank CM nanocapsules showed that 
these nanocapsules resulted in minimal cytotoxicity to UMUC3 cells at a 
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concentration of 0.5 mg/ml (Figure 4.11), which is much higher than that used 
in the evaluation of killing efficacy of CM-Dox1 and CM-PtALy2 (the 
maximum concentration was <0.05 mg/ml). This suggests that CM 
nanocapsules have good biocompatibility and are suitable as a drug delivery 
vehicle.  
 
Figure 4.11. Viability of UMUC3 cells after incubation with CM 
nanocapsules at different concentrations for 72 h in growth medium. Viability 
is expressed as a percentage relative to the control experiment carried out 
without nanocapsules. 
 
4.3.5  Synergistic Effects from Co-delivery of Dox and Pt-ALy via CM-
Dox-PtALy Nanocapsules  
Dual drug-loaded nanocapsules (CM-Dox-PtALy) were also evaluated for 
possible synergistic effects of Dox and Pt-ALy on UMUC3 cells. The efficacy 
of CM-Dox-PtALy in killing UMUC3 cells after 4 or 72 h-treatment is higher 
than either CM-Dox1 or CM-PtALy2 (Figure 4.8(c, d)), and this is reflected in 
the IC50(Dox) and IC50(Pt) of CM-Dox-PtALy which are much lower than that of 
CM-Dox1 and CM-PtALy2, respectively (Table 4.2). In order to identify the 
combination effects (antagonistic, additive or synergistic) arising from co-
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delivery of Pt-ALy and Dox via the dual drug-loaded nanocapsules, the CI 
was calculated and plotted in Figure 4.8(e, f). It can be seen from Figure 4.8(e, 
f) that for Fa values from 0.2 to 0.8, CI of CM-Dox-PtALy nanocapsules is 
much smaller than 1. CI of 1 is deemed the limit between antagonism (CI>1) 
and synergism (CI<1), and CI<0.5 is deemed strong synergism (Pandita et al., 
2014). These results thus indicate significant synergistic effects of Dox and 
PtALy in the CM-Dox-PtALy nanocapsules against UMUC3 cells. On the 
other hand, treatment of UMUC3 cells using a combination of free Dox and 
Pt-ALy (Figure 4.8(a, b)) at the same drug ratio as CM-Dox-PtALy showed 
minimal decrease in IC50(Dox), as compared with free Dox only. It suggests that 
the anti-cancer effects using a combination of free Dox and Pt-ALy are mainly 
attributed to the action of Dox, as the Pt-ALy has much lower killing efficacy 
on UMUC3 cells (Figure 4.8(a, b) due to its low uptake. Thus, most of the 
corresponding CI values for free Dox and Pt-ALy combinations are close to 1 
(Figure 4(e, f)), indicating no significant synergism was present for both 4 h 
and 72 h-treatment. Dox, an anthracycline chemotherapeutic agent, is 
commonly believed to initiate DNA damage via inhibition of topoisomerase II 
(Top II) (Minotti et al., 2004). The inhibition of Top II has also been proven to 
increase the sensitivity of tumor cells to CDDP, a DNA-modifying agent 
(Lippert, 1999), through alteration of kinetics of repair of damaged DNA (Ali-
Osman et al., 1993, Eder et al., 1995). Earlier studies have shown that 
combinations of a Top II inhibitor and CDDP give rise to synergistic activities 
against several cancers in vitro and/or in vivo (Bigioni et al., 2008, Lee et al., 
2010, Thigpen et al., 2004). In the present work, the difference in anti-cancer 
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effects between CM-Dox-PtALy and the free drug combination indicates that 
Dox and Pt-ALy were simultaneously delivered into the cancer cells via CM-
Dox-PtALy nanocapsules but not in free form. 
It can be seen from Table 4.2 that the magnitude of the difference in IC50(Drug) 
between each drug alone and in combination in the nanocapsules is affected by 
the treatment period. For Pt-ALy, IC50(Pt) of CM-Dox-PtALy is 5 times lower 
than that of CM-PtALy2 for 4 h-treatment and 16 times lower for 72 h-
treatment. For Dox, IC50(Dox) of CM-Dox-PtALy is ~6.5 times lower than CM-
Dox1 for 4 h-treatment compared to ~5 times for 72 h-treatment. The dose 
reduction indices (DRIPt and DRIDox) were also calculated to demonstrate the 
dose reduction of Pt-ALy and Dox in combination compared to each drug 
alone at various Fa values. As shown in Figure 4.12a, DRIPt and DRIDox 
values for 4 h-treatment increased from low Fa (0.2) to high Fa value (0.8). On 
the other hand, DRIPt values for 72 h-treatment are mainly >15 (Figure 4.12b), 
which are higher than those for 4 h-treatment except at high Fa. In contrast, 
DRIDox values for 72 h-treatment are similar to that for 4 h-treatment. The 
increase in DRIPt suggests that the presence of Dox in the CM-Dox-PtALy 
combination played a more important role in the synergistic anti-cancer effect 
for 72 h-treatment, compared to 4 h-treatment (Chou, 2010).  




Figure 4.12. DRI vs Fa plots of CM-Dox-PtALy against UMUC3 cells after 
treatment for 4 h (a) or 72 h (b). Full line represents the best fit curve through 
the data points. 
 
To further investigate the synergistic effects arising from co-delivery of Pt-
ALy and Dox via CM-Dox-PtALy, apoptosis assays were conducted for 
UMUC3 cells treated with Pt-ALy, CM-PtALy2 and CM-Dox-PtALy. As 
shown in Figure 4.13, at a dosage of 0.1 μg/ml [Pt] in all formulations, Pt-
ALy induces almost no necrosis and apoptosis with 4 h- and 72 h-treatment 
(only 3% of the cells showed early apoptosis for 72-h treatment). Treatment 
with CM-PtALy2 resulted in similar percentages of necrotic and apoptotic 
cells for both treatments (6% necrotic, 2%+2% apoptotic for 4 h-treatment and 
7% necrotic, 3%+4% apoptotic for 72-h treatment). These results indicate that 
the uptake of CM-PtALy2 into the cells via CM nanocapsules is quite rapid 
(within 4 h) and thus achieves a higher efficacy in killing UMUC3 cells than 
the free Pt-ALy drug, which is consistent with the MTT assay (Figure 4.8). 
The cellular Pt-uptake of CM-Dox-PtALy after 4 h-treatment is similar to that 
of CM-PtALy2 (Figure 4.9e(ii)), indicating that loading Dox into CM-PtALy2 
did not affect the uptake of Pt-ALy into the cells via the CM nanocapsules. At 
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the same Pt dosage (0.1 μg/ml [Pt]), CM-Dox-PtALy caused much higher cell 
necrosis (12%) and apoptosis (6%+7%) than CM-PtALy2 for 4 h-treatment. 
This increase in cell necrosis and apoptosis can thus be attributed to the 
presence of Dox. 
 
Figure 4.13. (a) Apoptosis assay of UMUC3 cells after treatment with Pt-
ALy, CM-PtALy2, and CM-Dox-PtALy nanocapsules (with equivalent [Pt] of 
0.1 μg/ml) for 4 h or 72 h at 37 ºC. The early apoptotic cells are presented in 
the lower right quadrant (R4), and late apoptotic cells are presented in the 
upper right quadrant (R2). PE-Texas Red-A channel was used to detect the 
propidium iodide signal. (b) Percentages of necrotic UMUC3 cells, cells in 
late and early apoptosis stages after 4 h- and 72 h-treatment. 




For 72 h-treatment, CM-Dox-PtALy induced ~2 times higher cell necrosis and 
late apoptosis and 1.5 times higher early apoptosis than the 4 h-treatment. In 
view of the comparable extent of cell necrosis and apoptosis caused by CM-
PtALy2 for both treatment times, the increase in necrosis and apoptosis with 
increasing treatment time with CM-Dox-PtALy can again be attributed to Dox 
in CM-Dox-PtALy. Thus, the more important role of Dox in the synergistic 
anti-cancer effect from CM-Dox-PtALy for 72 h-treatment compared to 4 h-
treatment can be rationalized from the apoptosis assays. 
4.3.6  Ex Vivo Evaluation of Mucoadhesivity and Effect of CM on 
Bladder Urothelium Morphology  
It is critical for nanocarriers intended for IDD application to be mucoadhesive 
in addition to having a suitable drug release profile and robust potency against 
the cancer cells. Herein, ex vivo simulation of nanocapsule instillation into the 
bladder was carried out using fresh porcine bladder to study the interaction 
and effects of the nanocapsules on the urothelium. Significant fluorescence 
was observed on the luminal surface of the bladder after incubation with 
FITC-labelled CM nanocapsules (FITC-CM) followed by rinsing with PBS, 
compared with the bladder treated with PBS (Figure 4.14). This indicates that 
the CM nanocapsules adhered strongly on the bladder wall, possibly due to 
electrostatic interactions between the amine groups of the CS chains on the 
surface of the nanocapsules with the urothelium.  




Figure 4.14. Volume view CLSM images of fresh porcine bladder urothelium 
after incubation with 5 mg/ml FITC-CM nanocapsules (a) or with artificial 
urine (A.U.) (b) for 4 h.  
 
The morphology of urothelium has been reported to be damaged by some 
mucoadhesive polymers like CS (Kos et al., 2006, Veranic et al., 2009). To 
investigate the effect of the CM nanocapsules, the urothelium morphology 
before and after exposure to these nanocapsules was compared using SEM. 
The SEM image at low magnification in Figure 4.15a shows that the bladder 
urothelium surface after exposure to A.U. for 4 h appeared intact and smooth. 
Figure 4.15b shows the urothelium morphology at higher magnification. The 
urothelium is reportedly covered by a mucin layer and uroplakin-covered 
superficial umbrella cells (GuhaSarkar and Banerjee, 2010). After treatment 
with CM nanocapsules (5 mg/ml) (comprising about 3.5 mg/ml CS as 
estimated based on feed ratio), the urothelium is covered with a whitish layer 
(Figure 4.15c). Higher magnification details of this layer in Figure 4.15d1 
suggest that this layer comprises CM nanocapsules that have successfully 
attached onto the bladder wall, consistent with the CLSM image in Figure 
4.12a. As shown in Figure 4.15d2, there is no evidence of damage to the 
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urothelium at the boundary between the parts covered by the nanocapsules and 
the uncovered parts. The morphology of the uncovered part is similar to that 
shown in Figure 4.15b. In contrast, the urothelium after treatment with CS 
solution (1 mg/ml in A.U. serving as positive control) exhibited evidence of 
extensive damage with exfoliation and disruption of the umbrella cells (Figure 
4.15(e, f)). This is in line with the report by Veranic et al., which showed the 
complete removal of the superficial layer of cells after instillation of CS 
dispersion (Veranic et al., 2009). The mucoadhesivity of the CM nanocapsules 
is a desirable property for IDD which can potentially increase the exposure 
time of cancer cells to the drug and enhance its delivery across the urothelium. 




Figure 4.15. SEM images of fresh porcine bladder urothelium after exposure 
to A.U. (a, b), 5 mg/ml CM nanocapsules (c, d1, d2) and 1 mg/ml CS (Positive 
control, e, f) for 4 h.  




In summary, positively charged CM nanocapsules have been prepared for 
loading Dox and CDDP either singly or in combination. By converting Dox to 
its hydrophobic form and by modifying CDDP with an amine-terminated 
peptide to Pt-ALy, Dox and Pt-ALy can be loaded into the nanocapsules with 
loading capacity of >90% and ~30%, respectively. The therapeutic effect of 
Pt-ALy (IC50(Pt) of 1.46 μg/ml) was significantly enhanced when delivered via 
CM nanocapsules (IC50(Pt) of 0.48 μg/ml). The dual drug-loaded nanocapsules 
(CM-Dox-PtALy) with 27% of Dox and 23.5% of Pt-ALy were more effective 
than the single drug-loaded nanocapsules against UMUC3 cells. The IC50(Pt) 
and IC50(Dox) of CM-Dox-PtALy after 4 h-treatment are 5 times and 6.5 times 
lower than that of CM-PtALy2 and CM-Dox1, respectively. After 72 h-
treatment, the IC50(Pt) and IC50(Dox) of CM-Dox-PtALy are 0.024 and 0.06 
μg/ml, which are 16 times and 5 times lower than those of CM-PtALy2 and 
CM-Dox1, respectively. Significant synergistic therapeutic effects (CI<1) via 
simultaneous delivery of these two drugs in CM-Dox-PtALy nanocapsules to 
the cells were observed. A comparison of DRI for 4 h- and 72 h-treatment 
indicates that Dox in CM-Dox-PtALy played a more important role in 
synergism when the treatment period is increased from 4 h to 72 h. These CS-
based nanocapsules demonstrate a high degree of biocompatibility and 
mucoadhesivity on the luminal surface of the bladder. Hence, the CM-Dox-
PtALy nanocapsule, with its sustained drug delivery property and significant 










CHAPTER 5 TARGETING HYBRID NANOGELS 
FOR POTENTIAL INTRAVENOUS CO-DELIVERY 







The focus in this Chapter is on targeting hybrid nanogels for potential 
intravenous application in ovarian cancer therapy. Unlike IDD discussed in 
Chapter 3 and Chapter 4, intravenous drug delivery systems face additional 
challenges, such as systemic elimination by the body’s immune system 
resulting in low circulation time, and systemic toxicity which results in 
adverse side effects. Targeting drug delivery systems (DDSs) for intravenous 
therapy have attracted vast attention in recent years (Gindy and Prud'homme, 
2009, Lee et al., 2012, McCarthy and Weissleder, 2008, Motornov et al., 2010, 
Park et al., 2009, Rahman et al., 2012, Rosenholm et al., 2011). As discussed 
in Section 2.2, there are two kinds of targeting mechanism: passive targeting 
and active targeting. In passive targeting, the enhanced permeability and 
retention (EPR) effect resulting from leaky and defective structure in tumor 
blood vessel, allows the DDS to accumulate at the tumor site. Active targeting 
DDSs aim to guide drugs to specific sites in organs or cells, and this is usually 
achieved by conjugating targeting ligands to the drug carriers (Lu and Low, 
2002, Nukolova et al., 2011, Winer et al., 2010). Since the FR is often 
overexpressed on many kinds of human cancers, while there is minimal 
expression in normal tissues, linking FR-targeting markers to the surface of 
NPs has been the most common and effective strategy for active targeting of 
tumors (Leamon and Reddy, 2004, Lu and Low, 2002, Ross et al., 1994, 




However, one of the most serious obstacles faced by DDS is clearance by the 
MPS (Harris and Chess, 2003), resulting in a drastic reduction in the DDS 
circulation life time in vivo (Gref et al., 1994, Moghimi et al., 2001). To 
overcome this problem and achieve macrophage evasion, nanoparticles (NPs) 
of <100 nm which are neutral (or slightly negative) and hydrophilic are highly 
desired as a matrix for loading and delivery of chemotherapeutic agents 
(Duncan, 2003, 2006, 2011, Gaspar and Duncan, 2009, Moghimi et al., 2001). 
Nanogels, as one type of such materials, have attracted much interest as a 
DDS for cancer therapy (Hamidi et al., 2008, Raemdonck et al., 2009, Yallapu 
et al., 2011). They are increasingly being explored for incorporating inorganic 
NPs (such as quantum dots and metallic NPs) into multifuntional platforms 
(Wu et al., 2010, Wu et al., 2011), as discussed in Section 2.1. The PAm-
based nanogels used in Chapter 3 have been shown to be a drug delivery 
vehicle that can avoid clearance by the MPS and effectively deliver the 
payload to the targeted cells or organs (Gao et al., 2006, Gao et al., 2008, 
Wenger et al., 2011, Winer et al., 2010).  
In the present work, MTX-functionalized Au/PAm hybrid nanogels (Au-PAm-
MTX) were designed with the three components: MTX (an active targeting 
ligand and therapeutic drug), Au NPs (for complexing with MTX and an 
anticancer agent) and hydrophilic PAm polymer (for macrophage evasion) for 
effective and targeted killing of cancer cells. MTX, an analogue of FA, can be 
used not only as a targeting ligand, but also as a chemotherapeutic agent for 




2007, Zeng et al., 2001). The toxicity of MTX is due to the inhibition of 
enzymes required in the folate metabolic pathway, and the blocking of DNA 
synthesis which leads to cell death (Castaldo et al., 2011). However, the target 
cancer cells may develop resistance to MTX via intracellular efflux mediated 
by multidrug resistance proteins (Zeng et al., 2001), which will greatly 
diminish the pharmacodynamics of the drug. The incorporation of Au NPs in 
the nanogel system is to enhance the anticancer effects and inhibit cell 
resistance to MTX. Ultra-small-sized gold (Au) NPs (e.g. ~2 nm or less) have 
been reported to be acutely toxic even at low dosages. Pan et al. have reported 
that 1.4 nm Au NPs could trigger necrosis, mitochondrial damage, and induce 
higher toxicity in a number of cell lines than 15 nm NPs (Pan et al., 2007). 
However, the preparation of 1.4 nm Au NPs is complicated, since it involves 
ligand exchange to obtain hydrophilic 1.4 nm Au NPs. Herein, a nanogel-
assisted method to incorporate small-sized Au NPs (1 nm~5 nm) in situ in the 
nanogels was developed. These Au NPs-incorporated hybrid nanogels 
remained very stable in water for over 6 months. Chen et al. have 
demonstrated the affinity of Au NPs for MTX (Chen et al., 2007), indicating 
that Au NPs can serve as a reservoir for MTX. Therefore, targeted co-delivery 
of toxic Au NPs and MTX via the hybrid nanogels is expected to result in 
effective killing of the FR-positive ovarian cancer cell line (KB), prevention of 






5.2 Materials and Methods 
5.2.1  Materials 
N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), folic acid (FA), methotrexate (MTX), sodium 
borohydride (NaBH4), gold (III) chloride hydrate (HAuCl4·3H2O), FITC-
labeled BSA, triethanolamine (TEA) were purchased from Sigma-Aldrich (St. 
Louis, MO). Folate-free RPMI-1640 medium was purchased from Invitrogen 
(Carlsbad, CA). KB cells and mouse macrophage cells (RAW264.7) were 
purchased from American Type Culture Collection. All other solvents and 
chemicals were similar to those described in Section 3.2.1. 
5.2.2  Preparation of Blank and FITC-encapsulated PAm-NH2 
Nanogels 
Amine-functionalized blank PAm nanogels (PAm-NH2) were prepared via the 
water/oil (W/O) microemulsion polymerization method described in Section 
3.2.2 with minor modification (Gao et al., 2008, Park et al., 2003). Am (0.611 
g), GDA (0.3 g) and APMA (90 mg) were used to prepare the PAm-NH2. 
After polymerization, the microemulsion was then divided into two portions. 
The solvent of one portion was then removed by rotary evaporation. The blank 
PAm-NH2 nanogels were purified as discussed in Section 3.2.2. The other 
portion was loaded with the Au NPs as discussed below. For FITC-
encapsulated PAm-NH2 nanogels (FITCen-PAm), the procedure was the same 
except that FITC-labeled BSA (5 mg) was added to the monomer mixture 




prepared in the same way except that APMA was not added. These nanogels 
were used for the preparation of Au hybrid nanogel without amine groups 
(next section). 
5.2.3  In situ Preparation of Au-PAm-NH2 Hybrid Nanogels 
Amine-functionalized Au-PAm-NH2 hybrid nanogel was synthesized by in 
situ loading of Au NPs in the blank nanogels in a W/O microemulsion system. 
HAuCl4 aqueous solution (10 mg/ml, ranging from 0.4 to 3.6 ml for Au-PAm1 
to Au-PAm5) was added into 10 ml of the microemulsion containing the as-
prepared PAm-NH2 nanogels. The mixture was sonicated in an ice bath for 
several minutes and this mixture quickly became a yellow transparent 
dispersion. Freshly prepared NaBH4 aqueous solution (85 mM) was slowly 
dripped into the dispersion until the molar ratio of NaBH4 to HAuCl4 was 
more than 3. The color of the dispersion changed from yellow to brown and 
then to dark red. The purification procedure was the same as that described for 
the blank nanogels. A non-amine-functionalized Au hybrid nanogel (NA-Au-
PAm3) was also similarly prepared using NA-PAm nanogel to serve as a 
control. 
5.2.4  Synthesis of FA- or MTX-functionalized Blank and Hybrid 
Nanogels 
In a typical experiment, MTX (6 mg) was dissolved in DMSO (2.5 ml) and 
then EDC (30 mg), NHS (6 mg) and TEA (10 μl) were added. This solution 
was sonicated for 10 min. 50 mg of an amine-functionalized nanogel (PAm-




7.4) was sonicated for 30 minutes, filtered through a 0.2-μm syringe filter, and 
placed in a 20 ml glass vial. The MTX solution was then added to the nanogel 
dispersion. The mixture was gently stirred for 4 h at 37 ºC. The MTX-
functionalized nanogels were then washed three times with DMSO/H2O mixed 
solvent (1:4, v/v) in an Amicon centrifugal filter unit and further dialyzed for 
three days against DI water in a dialysis tubing (molecular weight cutoff of 
12400 Da). To prepare other PAm-MTX nanogels (PAm-MTX1 to PAm-
MTX4), the weight of MTX was varied from 1.5 to 7.5 mg. FA-functionalized 
PAm, Au-PAm or FITCen-PAm nanogels (PAm-FA, Au-PAm3-FA or FITCen-
PAm-FA) were also synthesized using a similar procedure except that 6 mg 
FA was used instead of 6 mg MTX. The FA or MTX content in the nanogels 
was determined using UV-visible spectroscopy, based on standard calibration 
of the absorbance at 366 nm with FA and MTX of predetermined 
concentrations in DI water with 0.1% TEA (R2>0.99). The corresponding 
nanogels without FA and MTX were used as a control. 
5.2.5  Cellular Uptake of FITCen-PAm-FA and Au-PAm-MTX 
Nanogels 
KB is known to be a cell line that over-expresses the folate receptor, and it 
was chosen as the cancer cell model for our study. To investigate the cellular 
uptake of FITCen-PAm-FA nanogels in vitro, KB cells and macrophages were 
first cultured with folate-free RPMI-1640 medium supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/glutamine at 37°C and 5% CO2, 




per well. 1 ml medium containing 1 mg/ml FITCen-PAm-FA (or FITCen-PAm) 
nanogels was then added to each well. After 4 h incubation at 37 °C, the 
medium was removed and the cells were washed three times with PBS (pH 7.4) 
to remove the unattached nanogels. The cells were fixed with 4% 
formaldehyde in PBS for 15 min, and a fluorescence microscope with a FITC 
filter (Zeiss LSM 510 Meta, Germany) was used to observe the cells.  
To quantify and visualize the uptake of Au-PAm-MTX, inductively coupled 
plasma-mass spectrometry (ICP-MS) and dark field light scattering 
microscopy were utilized, respectively. KB cells and macrophages were 
seeded in 8-well culture plates at a density of 5×105 cells per well for 24 h. For 
light scattering analysis, sterile cover-slips were placed at the bottom of each 
well in the culture plates before cell seeding. The cells was cultured with fresh 
medium containing the nanogels (Au-PAm3-MTX, Au-PAm5-MTX, or NA-
Au-PAm3) at the desired concentration (0.2 or 1 mg/ml) for 4 h. After the 
incubation period, the cells were washed three times with PBS. For light 
scattering analysis, the cells were then fixed with 4% formaldehyde in PBS for 
15 min and the cover slip was placed on a glass slide in the chamber of a dark 
field light scattering microscope at room temperature. For the ICP-MS 
experiments, the concentration of the gold ions was determined using a HP 
7500a inductively coupled plasma mass spectrometer as discussed in Section 
4.2.10.  




The cytotoxicity of the nanogels was evaluated by determining the viability of 
KB and macrophage cells after incubation in medium containing the nanogels 
at concentrations ranging from 0.1 to 1 mg/ml. Cell viability was tested by a 
standard MTT assay with minor modifications. The cells were seeded at a 
density of 104 cells per well in a 96-well plate with 100 μl RPMI-1640 
medium supplemented with 10% fetal bovine serum (FBS), 1 mM L-
glutamine and 100 IU/ml penicillin. After incubation for 24 h (37 °C, 5% 
CO2), the medium in each well was aspirated off and replaced with 100 μl of 
fresh medium containing 0.1 to 1 mg/ml of nanogels. The nanogel-containing 
culture medium was sterilized by passing through a 0.2-μm syringe filter prior 
to incubation. After incubation for another 24 h, the nanogel-containing 
culture medium in each well was replaced by 90 μl of medium and 10 μl of 
MTT solution (5 mg/ml in PBS). MTT assay was carried out as described in 
Section 3.2.8. The results were expressed as percentages relative to the optical 
absorbance obtained in the control experiments which were carried out using 
the culture medium without nanogels. 
To determine the in vitro targeted killing efficacy of FA or MTX-
functionalized nanogels (PAm-FA, PAm-MTX1 to PAm-MTX4, Au-PAm3-
FA, Au-PAm3-MTX and Au-PAm5-MTX), the MTT assay was used to test 
the viability of KB and macrophage cells after incubation with FA-free RPMI-
1640 medium containing 0.1 to 1 mg/ml of these nanogels. After 4 h of 
incubation, the medium was removed and the cells were then incubated with 




assay. Except for these differences, the MTT assay was the same as that 
described above for the cytotoxicity assay. NA-Au-PAm3 nanogels without 
MTX were also evaluated in the same way for comparison. 
5.2.7  Characterization 
The morphologies of blank and hybrid nanogels were recorded on a JEOL 
2100F transmission electron microscope as discussed in Section 3.2.4. The 
blank nanogels (but not the hybrid nanogels) were stained with 2% (w/v) 
phosphotungstic acid aqueous solution for 15 min prior to the observations to 
enhance the contrast. The hydrodynamic size and zeta potential of the 
nanogels dispersed in water were determined on a zeta-sizer nanosystem as 
discussed in Section 3.2.4. Sample dispersions were filtered through a 0.2-μm 
pore size membrane filter before the measurements. Each measurement was 
repeated at least three times and the results were reported as average ± 
standard deviation. UV–visible absorption spectra of the Au-PAm-NH2 hybrid 
nanogels dispersion (1 mg/ml in water) in the wavelength range of 200–800 
nm were recorded on a Shimadzu UV-3101PC spectrophotometer. The 
chemical composition of the Au-PAm-NH2 hybrid nanogels was also 
determined by X-ray photoelectron spectroscopy (XPS) as discussed in 
Section 4.2.5. To compensate for surface charging effect, all core-level spectra 
were referenced to the C 1s hydrocarbon peak at 284.6 eV. FTIR spectra of 
MTX-functionalized nanogels dispersed in KBr pellets were recorded on a 






Figure 5.1. Schematic diagram illustrating (a) the synthesis of Au-PAm-NH2 
hybrid nanogels, via (i) in-situ reduction of HAuCl4 in amine-functionalized 
PAm nanogels after W/O microemulsion polymerization and (ii) surface 
functionalization with FA or MTX, and (b) proposed mechanism of targeted 
co-delivery of Au NPs and the drug via receptor-mediated endocytosis. 
 
5.3 Results and Discussion 
5.3.1  Preparation and Characterization of Au-PAm-NH2 Hybrid 
Nanogels  
Au-PAm-NH2 hybrid nanogels were synthesized as shown by Step (i) of 
Figure 5.1a: the preparation of the PAm-NH2 nanogels was first initiated in a 




of gold ions was then carried out with NaBH4 in the same microemulsion 
under sonication. The TEM image of blank PAm-NH2 nanogels (stained with 
phosphotungstic acid, Figure 5.2a) shows that these nanogels are uniform and 
round, with a diameter of 20-30 nm. The hydrodynamic diameter as 
determined from DLS is about 31 nm (Figure 5.2e), which is consistent with 
the TEM results. The TEM images of the different Au-PAm-NH2 hybrid 
nanogels are shown in Figure 5.2(b-d). As shown in the insets of Figure 5.2, 
with a 9-fold increase in gold ions in the reaction mixture, the size of the Au 
NPs increases from 1~3 nm (b) to 5~7 nm (d). At the same time, the number 
of Au NPs also increases significantly (comparing the sequence from (b) to (d) 
in Figure 5.2). These two factors account for the increase in gold content of 
the nanogel with increasing gold ion concentration in the reaction mixture 
(Figure 5.3). The Au content in hybrid nanogels as determined by ICP-MS 
and XPS increases almost linearly with the increase in HAuCl4 concentration. 
These results are consistent with the surface plasmon resonance (SPR) results 
in Figure 5.4 which show a red shift in the SPR peak from a broad peak at 
about 510 nm to a narrow peak at 525 nm, and a corresponding increase in the 






Figure 5.2. TEM images of PAm-NH2 nanogels without (a) and with Au NPs 
(b-d, Au-PAm1, Au-PAm3, and Au-PAm5) prepared with different amounts 
of HAuCl4. The insets show the HRTEM image of Au NPs of each sample. (e) 
Dynamic light scattering and (f) Zeta potential results of blank PAm-NH2 
nanogels (red, R), and Au-PAm1 (green, G) and Au-PAm5 (blue, B) hybrid 






Figure 5.3. Au content of nanogels (Au-PAm1 (1) to Au-PAm5 (5)) from 
ICP-MS (a) and XPS (b) analyses. 
 
 
Figure 5.4. UV-vis absorption spectra of PAm-NH2 nanogels without (Blank) 
and with Au NPs (Au-PAm1 to Au-PAm5). The inset shows the image of 
aqueous dispersions of the nanogels at a concentration of 1 mg/ml after 6 






The in-situ reduction of gold ions was carried out in the absence of a 
stabilizing agent. Since hydrophilic agents are often used to stabilize 
hydrophobic Au NPs in water, the observed well-dispersed Au NPs in Figure 
5.2 must be stabilized by the nanogels. The DLS results in Figure 5.2e show 
that the hydrodynamic diameters of the blank and hybrid nanogels are quite 
similar, and there is no indication of nanoparticles smaller than 10 nm (Au 
NPs are < 10nm as shown in Figure 5.2) in the Au-PAm-NH2 hydrid nanogels. 
Similarly, Figure 5.2f shows that the zeta potential of each hybrid nanogel has 
only one peak which is similar with that of the blank nanogel. If the Au NPs 
and nanogels exist independently in the dispersion, at least two separate peaks 
are expected for size or zeta potential of each hybrid Au-PAm-NH2 nanogel. 
Therefore, it it believed that the in-situ-synthesized Au NPs do not exist 
independently of the nanogels, but rather, they are well-stabilized via 
incorporation into/onto the PAm-NH2 nanogels. When HAuCl4 was added to 
the reaction mixture for the preparation of the Au NPs, it as well as H2O was 
absorbed into the network of the hydrophilic PAm-NH2 nanogels in the W/O 
microemulsion before it was reduced in-situ to Au NPs. Hence, the nanogels 
serve as the support matrix for the as-formed hydrophobic metallic particles. 
As shown in Figure 5.3, the Au content in the nanogels can be easily 
controlled by changing the HAuCl4 reactant concentration. The Au-PAm-NH2 
nanogels disperse well in aqueous medium and the dispersion is stable for 





Figure 5.5. Comparison of hydrodynamic diameter of freshly prepared PAm-
NH2 nanogels without (Blank) and with Au NPs (Au-PAm3 to Au-PAm5) and 
the corresponding sample after 6 months in water.  
 
5.3.2  MTX- or FA-functionalization of Blank and Hybrid Nanogels  
In this work, FA and its analogue, MTX, were used as a targeting ligand (and 
in the case of MTX, also as a drug). They were conjugated to the amine-
functionalized PAm blank and hybrid nanogels via carbodiimide chemistry 
(Step (ii) of Figure 5.1a). The success of the conjugation of MTX to the 
nanogels can be ascertained by comparing the FTIR spectra of the nanogels 
before and after the modification. Figure 5.6 shows the FTIR spectra of PAm-
NH2 nanogels without MTX, MTX-functionalized PAm-NH2 (PAm-MTX4) 
and MTX-functionalized Au-PAm-NH2 hybrid (Au-PAm3-MTX) nanogels. 
The absorbance bands at 1507 cm-1, 1524 cm-1, and 1559 cm-1, which are 
absent in the spectra of PAm (Figure 5.6a), appear in the spectra of both PAm-
MTX3 (Figure 5.6b) and Au-PAm3-MTX (Figure 5.6c). These bands are 




and the amide linkage formed between the primary amine of the nanogels and 
the carboxylic acid of MTX. The two bands at around 1214 cm-1 and 1127 cm-
1 in Figure 5.6a correspond to the C-O stretching vibrations of the aliphatic 
ester in the nanogels. According to the standard absorption spectrum of 
aliphatic ester, the peak at 1127 cm-1 should be weaker than that at 1214 cm-1 
(Kuptsov and Zhizhin, 1998). However, this is not the case for the spectrum of 
the PAm-NH2 nanogel in Figure 5.6a. This can be explained by the fact that 
the C-N stretching peak of the primary amine on PAm-NH2 nanogels (from 
the copolymerization of the amine-functionalized monomer, APMA) is also 
located at 1127 cm-1. This result indicates that primary amine-functionalized 
nanogels were successfully prepared with the GDA cross-linker, which has 
been reported to be biodegradable (Gao et al., 2008). Correspondingly, the 
decrease in the intensity of the band at 1127 cm-1 in Figure 5.6(b, c) suggests a 
consumption of the primary amine, which further indicates the chemical 
conjunction of MTX onto the nanogels (both with or without Au NPs) via 





Figure 5.6. FT-IR spectra of (a) PAm-NH2 nanogel, (b) PAm-MTX3 nanogel, 
and (c) Au-PAm3-MTX nanogel. 
 
The amount of MTX incorporated in the nanogels was quantified using UV-
visible spectroscopy and listed in Table 5.1. For MTX-functionalized PAm 
nanogels, the mass of MTX per milligram nanogel increased with increasing 
MTX in the reaction mixture. The presence of Au NPs in the nanogels can 
affect the loading efficiency of MTX, and with a high Au content in the 
nanogels, the amount of MTX incorporated increases very significantly 
(comparing Au-PAm5-MTX with Au-PAm3-MTX and PAm-MTX3 in Table 
5.1). These results suggest that Au NPs may have played an important role in 
the incorporation of MTX in the nanogels. The affinity of Au NPs for MTX 
has been reported and MTX-adsorbed Au NPs have been investigated for 
inhibition of tumor growth (Chen et al., 2007). Due to its higher affinity for 




agent. In the present work, it is postulated that in the Au-PAm-MTX nanogels, 
MTX is chemically conjugated to the PAm polymer and physically adsorbed 
on the Au NPs, and this postulate is discussed in greater detail below. 
Table 5.1. MTX content and zeta potential (ζ) of MTX-functionalized 
nanogels. 
Sample MTX in feed (mg) 
MTX content in 
nanogels (μg/mg) 
ζ before MTX 
incorporation 
(mV) 
ζ after MTX 
incorporation 
(mV) 
PAm-MTX1 1.5 12.2±1.5 -- -- 
PAm-MTX2 4.5 23.5±4.4 -- -- 
PAm-MTX3 6 32.6±0.7 20.8±0.9 14.7±0.2 
PAm-MTX4 7.5 41.1±2.0 20.8±0.9 12.0±0.5 
Au-PAm3-MTX 6 34.8±1.7 16.5±1.2 -3.2±0.6 
Au-PAm5-MTX 6 43.8±3.1 13.9±0.6 -14.6±0.5 
--Not tested. 
 
5.3.3  Cellular Uptake and Cytotoxicity of FA-functionalized Nanogels  
PAm-FA nanogels with entrapped FITC-labeled BSA (FITCen-PAm-FA) were 
used to evaluate its targeting specificity for KB cells. The uptake of FITCen-
PAm-FA nanogels and FITCen-PAm nanogels by KB and macrophages was 
examined by fluorescence microscopy. As shown in Figure 5.7, strong 
fluorescence can be only observed from the images of KB cells cultured with 
FITCen-PAm-FA (Figure 5.7c), while macrophages show a very low signal 
with both FITCen-PAm-FA (Figure 5.7d) and FITCen-PAm (Figure 5.7b). 
These results indicate that while FA enables the nanogels to be internalized 
rapidly by KB cells via FR-mediated endocytosis since the folate receptor is 
over-expressed in these cells (Ross et al., 1994), the FA-functionalized PAm 




nanogels without FA can only enter the cancer cells by the non-specific 
binding/penetration process, and the weak fluorescent signal obtained with 
these nanogels (Figure 5.7a) indicates that uptake by this route is much lower 
compared to the FR-mediated pathway. Interestingly, a comparison of Figure 
5.7b and 5.7d shows that with macrophages, a stronger signal was obtained 
with FITCen-PAm than FITCen-PAm-FA. The amine groups of FITCen-PAm 
confer positive charges to the nanogel (ζ of ~20.3 mV) which may interact 
with the negative components on the cell membranes and enhance the uptake 
of the nanogels. On the other hand, when the amine groups are utilized for FA 
conjugation, the positive charges of the FITCen-PAm-FA nanogels decreased 
(ζ of ~14.6 mV).  
 
Figure 5.7. Fluorescence microscopy images of KB and macrophage cells 
after culturing in medium containing 1 mg/ml FITCen-PAm (a, b) or FITCen-






Figure 5.8. Viability of KB and macrophage cells after incubation with PAm-
FA nanogels at different concentrations for 24 h. Control experiments were 
carried out without nanogels. 
 
The toxicity of materials to be used for drug delivery is of great concern. It is 
critical that the nanogels after modification with the targeting ligand retain 
their low toxicity. The results of the cytotoxicity assay of KB and 
macrophages after incubation with PAm-FA nanogels at concentrations of 0.1, 
0.2, 0.5, and 1.0 mg/ml for 24 h are given in Figure 5.8. The viabilities of 
these two types of cells are above 90% over the range of nanogel 
concentration tested, and are not significantly different from that in the control 
experiment. Therefore, it can be concluded that FA-functionalized PAm 
nanogels of concentration up to 1 mg/ml exhibit very low cytotoxicity to these 
types of cells, and will be suitable as a carrier for targeted drug delivery. It has 
been reported that degradable PAm nanogels which are non-amine-
functionalized have low cellular toxicity on rat C6 glioma cells (viability of 
93% ± 5%) (Gao et al., 2008). Cytotoxicity assays carried out with KB and 




shown in Figure 5.9. As mentioned above, the interaction of amine groups 
with the cell membrane enhances the uptake of the nanogels by macrophages. 
This results in the PAm-NH2 exhibiting higher cytotoxicity towards the 
macrophages as compared with NA-PAm nanogels (Figure 5.9).  
 
Figure 5.9. Viability of macrophages and KB cells after incubation with 
amine-functionalized and non-amine-functionalized PAm nanogels (PAm-
NH2 and NA-PAm, respectively) at different concentrations for 24 h. Control 
experiments were carried out without nanogels.  
 
5.3.4  Cytotoxicity of Au NPs Incorporated into NA-PAm Nanogels 
 For a more accurate assessment of the toxicity of Au NPs on cells, a non-
amine-functionalized Au hybrid nanogel (NA-Au-PAm3, similar gold content 
as Au-PAm3) was used instead of Au-PAm3 which has primary amine groups. 
Figure 5.10(a, b) shows that the viability of KB cells incubated with NA-Au-
PAm3 decreases with increasing nanogel concentration. Since the non-amine 
functionalized blank nanogel (NA-PAm) is not cytotoxic to the KB cells (as 
shown in Figure 5.9), these results suggest that Au NPs in the nanogels are 




However, the macrophages are also adversely affected by NA-Au-PAm3 and 
their viability decreased to 64% after 4 h treatment at 1 mg/ml and 24 h 
incubation, although after 72 h incubation there is some recovery in the 
macrophage viability. It should be noted that the viability of macrophages is 
higher than that of KB cells at all concentrations of NA-Au-PAm3 tested, and 
especially at high concentration. This may be due to the hydrophilicity of the 
nanogel which can reduce its uptake by macrophages. Since the Au NPs are 
cytotoxic towards KB cells, they can be a useful anti-cancer agent for cancer 
therapy if targeted delivery is possible. This is discussed in greater detail in the 
next section.  
 
Figure 5.10. Viability of KB cells (solid symbols) and macrophages (open 
symbols) after incubation with NA-Au-PAm3 at different concentrations for 4 
h followed by another 24 or 72 h in fresh growth medium. Control 
experiments were carried out without nanogels. 
 





MTX, an analogue of FA, can serve as a targeting ligand similar to FA, but 
unlike FA, it has cytotoxic properties. The anti-cancer effects of Au NPs 
and/or MTX in the nanogels was accessed using PAm-FA, Au-PAm3-FA, 
PAm-MTX3, and Au-PAm3-MTX. Figure 5.11 shows the viability of KB 
cells (expressed as percentage of cells that survive the treatment) as a function 
of the nanogel concentration in the incubation medium. Figure 5.11a shows 
that PAm-FA results in minimal cytotoxicity to the KB cells, which is 
expected since FA is known to be non-cytotoxic and Figure 5.9 has shown that 
PAm-NH2 up to 1 mg/ml also did not adversely affect the KB cells. In the case 
of Au-PAm3-FA (Figure 5.11b), the KB cells demonstrated decreasing 
viability with increasing nanogel concentration in the 24 h period after being 
treated with this nanogel (treatment period of 4 h). These results indicate that 
the Au NPs in Au-PAm3-FA nanogels are responsible for killing the KB cells. 
The treatment of KB cells with PAm-MTX3 (Figure 5.11c) also results in a 
decrease viability of the KB cells after 24 h. The comparison of Figure 5.11c 
and 6a thus illustrates the cytotoxicity of MTX even though it is conjugated to 
the PAm-NH2 nanogels via amide bonds. The MTX may be released from the 
nanogel in the cytoplasm of the KB cells via the degradation of the amide 
bond (Kohler et al., 2005). However, after 72 h the KB cells seem to recover 
from the cytotoxic effects of PAm-MTX3 (Figure 5.11c). It can be seen that 
PAm-MTX3 (with MTX of 41.1 μg/mg) kills only about 37% of the KB cells 
after 24 h even at a dosage of 0.5 mg/ml. Thus, with time, the remaining 
viable cells can still propagate, and/or there may also be cellular efflux of the 




from the nanogel in cytoplasm. These PAm nanogels have been reported to 
degrade under cytoplasmic conditions within an hour (Gao et al., 2008), which 
may lead to the rapid intracellular accumulation of free MTX within the first 
day. A smaller degree of recovery after 72 h was also observed for KB cells 
incubated with Au-Pam3-FA (Figure 5.11b) 
 
Figure 5.11. Viability of KB cells after incubation with PAm-FA (a), Au-
PAm3-FA (b), PAm-MTX3 (c) and Au-PAm3-MTX nanogels (d) at different 
concentrations for 4 h followed by another 24 (solid symbols) or 72 h (open 
symbols) in fresh growth medium. Control experiments were carried out 





The viability of KB cells treated with Au-PAm3-MTX is shown in Figure 
5.11d. After treatment with Au-PAm3-MTX at high dosage (0.5mg/ml or 
higher), the viability of the KB cells after 24 h incubation is similar to what is 
observed with Au-PAm3-FA (Figure 5.11b). This indicates that Au NPs play 
the key role in killing most of the KB cells at high dosage. At dosages of <0.5 
mg/ml, the killing efficacy of KB cells by Au-PAm3-MTX is only a little 
higher than that of Au-PAm3-FA. This level of killing efficacy may appear 
lower than that expected from the combined effects of Au NPs (as shown by 
Au-PAm3-FA in Figure 5.11b), and MTX (as shown by PAm-MTX3 in 
Figure 5.11c). However, a direct comparison of Figure 5.11d with 6c is not 
possible since the amount of these nanogels taken in by the cells may not be 
the same at the same nanogel concentration in the medium because of the 
differences in the nanogel characteristics (e.g. surface MTX concentration and 
zeta potential). 
It can be seen from Figure 5.11d that after 72 h incubation, the viability of KB 
cells is similar to that after 24 h incubation at dosages of 0.5 mg/ml and higher. 
This indicates that the recovery of the KB cancer cells has been suppressed at 
these dosages. This suppression of recovery is not observed for PAm-MTX3 





Figure 5.12. Viability of KB cells (solid symbols) and macrophages (open 
symbols) after incubation with Au-PAm-MTX nanogels at different 
concentrations for 4 h followed by another 24 (a) or 72 h (b) in fresh growth 
medium. Control experiments were carried out without nanogels.  
 
The comparison of Au-PAm3-MTX and Au-PAm5-MTX on killing efficacy 
of KB cells was also carried out and shown in Figure 5.12(a, b). Surprisingly, 
although Au-PAm5-MTX has a much higher Au content (89.3 ± 1.9 μg/mg) 
than Au-PAm3-MTX (26.9 ± 0.3 μg/mg), the viability of KB cells with these 
two nanogels is quite similar especially after 24 h incubation. This finding 
may be due to the fact that Au-PAm5 contains bigger Au NPs than Au-PAm3 
(Figure 5.2), and bigger Au NPs have lower cytotoxicity than the smaller ones, 
as will be discussed in the last section. 
5.3.6  Macrophage Evasion of PAm-MTX and Au-PAm-MTX Hybrid 
Nanogels  
For an effective targeted delivery, the ability to evade the MPS (such as 




as the ability to kill the cancer cells. The viability of macrophages was 
investigated using the same incubation conditions as for the KB cells. Figure 
5.13a and Figure 5.12 show that macrophage viability remains high for both 
PAm-MTX and Au-PAm-MTX nanogels. Comparing Figure 5.13a with 
Figure 5.11c, it can be seen that the PAm-MTX nanogel only kills KB cancer 
cells but spares the macrophages. As discussed above, Au NPs incorporated 
in/onto nanogels caused cytotoxic effects to macrophages (Figure 5.10.). 
However, when FA or MTX is incorporated, the Au-PAm3-FA and Au-
PAm3-MTX nanogels pose no toxic effects to macrophages after 24 h 
incubation even at high dosage (1mg/ml, Figure 5.13b), unlike the cytotoxic 
effects on KB cells. The same results were obtained after 72 h incubation 
(Figure 5.13(c, d)). The FA- or MTX-functionalized hybrid nanogels’ lack of 
cytotoxicity towards macrophages can be attributed to the incorporation of 
MTX (or FA), which will be discussed in the last section. Therefore, co-
delivery of Au NPs and MTX by the hybrid nanogels (Au-PAm-MTX) (as 
illustrated in Figure 5.1b) serves three important aspects for active targeted 






Figure 5.13. Viability of macrophages after incubation with PAm-MTX (a, c), 
and Au-PAm-MTX(or FA) nanogels (b, d) at different concentrations for 4 h 
followed by another 24 h (a, b) or 72 h (c, d) in fresh growth medium. Control 
experiments were carried out without nanogels. 
 
5.3.7  Targeting Effect of Au-PAm-MTX Hybrid Nanogels 
The targeting effect of the Au-PAm-MTX nanogels on KB cells can be 
demonstrated by observation of the cells after incubation with the Au hybrid 
nanogels under a dark field light scattering microscope. Figure 5.14(a, d) 
shows the light scattering images of the KB and macrophage cells in the 
absence of nanogels. It is clear that both types of cells show weak light 
scattering, which is likely due to autofluorescence and scattering from 




nanogels, the macrophages show a few enhanced light-scattered dots from the 
Au NPs (Figure 5.14b, c), but the light-scattering intensity from the KB cells 
(Figure 5.14e, f) is far higher than that from the macrophages, indicating an 
increased uptake of Au NPs by the over-expressed folate receptors on the 
surface of the carcinoma cells. These results confirm that the Au-PAm-MTX 
nanogels can evade the macrophages. By comparing the light-scattering 
images from KB cells incubated with Au-PAm3-MTX and Au-PAm5-MTX 
nanogels at the same dosage of 1 mg/ml, it can be seen that many more light 
scattering dots were obtained with Au-PAm5-MTX (Figure 5.14f) than with 
Au-PAm3-MTX (Figure 5.14e) due to the higher gold content in the former. 
The morphology of the KB cells treated with the MTX-loaded hybrid nanogels 
(Figure 5.14e, f) is different from that of the control (Figure 5.14d) since the 
uptake of these nanogels has compromised the viability of these cells. 
 
Figure 5.14. Dark-field light scattering images of KB cells and macrophages 
cultured in medium containing Au-PAm3-MTX (1 mg/ml: b, e) or Au-PAm5-
MTX (1 mg/ml: c, f) hybrid nanogels for 4 h at 37 °C in a humidified 
atmosphere with 5% CO2. The control was cultured in medium without 





The differential delivery of the MTX-functionalized Au-PAm hybrid nanogels 
to KB cells and macrophages was further quantified by ICP-MS. It can be 
observed from Figure 5.15 that after 4 h treatment with the same nanogel at a 
dosage of 0.2 or 1 mg/ml, KB cells take in much more Au NPs (by 3-4 times) 
than macrophages. This result is consistent with the microscopy images in 
Figure 5.14, and the preferential killing of KB cells by the MTX-
functionalized Au-PAm hybrid nanogels over macrophages (as shown by 
comparing Figure 5.11d and 5.13b). Figure 5.15 also shows that Au-PAm5-
MTX is taken up to a higher extent (by 2.5-3 times) than Au-PAm3-MTX by 
either cell line at the same dosage. For example, treatment of KB cells with 
Au-PAm5-MTX at 0.2 mg/ml results in a gold uptake of 0.173 pg/cell, which 
is above 3 times higher than that with Au-PAm3-MTX (0.050 pg/cell). 
However, the effects on the KB cells are quite similar. As shown in Figure 
5.12a, with 0.2 mg/ml Au-PAm5-MTX, 73% of the cells remained viable after 
1 day incubation, and the corresponding value for Au-PAm3-MTX is 72.5%. 
The amount of MTX taken in by the cells can be estimated from the Au and 
MTX contents in the nanogels (Figure 5.3 and Table 5.1) and the amount of 
Au taken in by the cells after incubation with the MTX-functionalized Au-
PAm hybrid nanogels. Hence, the amount of MTX taken in by the cells after 
incubation with 0.2 mg/ml of Au-PAm5-MTX and Au-PAm3-MTX was 
estimated to be 0.083 and 0.065 pg MTX/cell, respectively. Since the amount 




Au NPs (Au-PAm3-MTX) cause greater toxicity to KB cells than the bigger 
Au NPs (Au-PAm5-MTX).  
 
Figure 5.15. Uptake of Au-PAm-MTX hybrid nanogels at a dosage of 1 
mg/ml (a) and 0.2 mg/ml (b) by KB and macrophage cells after incubation for 
4 h at 37 °C in a humidified atmosphere with 5% CO2. The control (Blank) 
was cultured in fresh medium without nanogels. 
 
Figure 5.16. Macrophage uptake of different kinds of hybrid nanogels with 
and without MTX after incubation for 4 h at 37 °C in a humidified atmosphere 





In order to explain why incorporation of MTX can reduce the toxicity of Au 
hybrid nanogels to macrophages, the uptake of NA-Au-PAm3 (ζ of about -9 
mV) and Au-PAm3-MTX (ζ of about -3 mV) by macrophages after 4 h 
treatment was compared. These two nangels also have similar size and gold 
content (about 27 μg Au/mg nanogels). Figure 5.16 shows that at the same 
concentration of 1 mg/ml, NA-Au-PAm3 was taken in by the macrophages 
(0.23 pg Au/cell) to a greater extent than Au-PAm3-MTX (0.04 pg Au/cell). 
Even the uptake of Au-PAm5-MTX (ζ of about -14.6 mV), which has a high 
Au loading (about 89 μg Au/mg nanogel) by the macrophages resulted in only 
0.13 pg Au/cell, which is still lower than that observed with NA-Au-PAm3. 
Such high uptake of NA-Au-PAm results in 64% viability of macrophage after 
24 h incubation (Figure 5.10a), compared with about 100% viability for Au-
PAm3-MTX and Au-PAm5-MTX (Figure 5.13b). A similar trend was 
obtained with 0.2 mg/ml nanogels. These findings indicate that the naked Au 
NPs (i.e. not associated with MTX) can stimulate phagocytosis by the 
macrophages. It has been reported that naked Au NPs are likely to precipitate 
in presence of high salt or in vivo environment due to their high surface 
activity (Zhang et al., 2012). Although in the present work, the Au NPs were 
incorporated into/onto nanogels which are stable in the culture medium, the 
Au NPs that are located at the surface of nanogels will interact with proteins in 
medium or receptors on the cellular surface and promote uptake by 
macrophages, as illustrated in Figure 5.17. As discussed above, when MTX 




cover these active surfaces due to it affinity to Au NPs (Chen et al., 2007). As 
the PAm matrix is very hydrophilic and thus unlikely to induce uptake by 
macrophages, the MTX modified Au-PAm hybrid nanogels would be able to 
evade the clearance by macrophages (Figure 5.17). Therefore, as indicated in 
Figure 5.16, the uptake of these Au-PAm-MTX nanogels by macrophages is 
much reduced compared to naked NA-Au-PAm3 and thus results in lower 
cytotoxicity. 
 
Figure 5.17. Schematic diagram illustrating macrophage uptake of NA-Au-
PAm nanogels via Au NPs-assisted endocytosis, and the macrophage-evasive 





5.4  Conclusion 
Targeting PAm-based hybrid nanogels can be readily synthesized via water/oil 
microemulsion polymerization followed by in-situ reduction of gold and 
conjugation of FA or MTX. Treatment of KB cells and macrophages with 
these nanogels has shown that these nanogels have several distinct advantages 
as a DDS. The size and hydrophilicity of the nanogels minimize uptake by 
macrophages and can potentially increase their circulation life times. 
Conjugation of targeting ligands or drugs, such as FA and MTX enables the 
DDS to actively target FR-positive cancer cells. Since the nanogels were 
prepared with a degradable cross-linker, it is expected to be rapidly 
biodegraded under cytoplasmic conditions to release their cargo in the targeted 
cells. The toxic Au NPs in the nanogels have affinity for MTX and can be 
used to increase the drug loading, enhance the anticancer efficacy and 
overcome the recovery of cancer cells. Our in vitro experiments have shown 
that 1 mg/ml of Au-PAm3-MTX hybrid nanogels can kill more than 80% of 
KB cells without significant cytotoxicity to macrophages. Thus, this system 
can potentially be intravenously applied for active targeted co-delivery of Au 











CHAPTER 6 CONCLUSIONS AND 





This thesis has attempted to develop soft nanoparticles as DDSs for potential 
chemotherapy of NMIBCs and ovarian cancers. For targeting or site-specific 
delivery of drugs, different types of soft nanoparticles were synthesized, and 
the potential uses of these drug(s)-loaded nanoparticles via intravenous or 
intravesical administration were investigated. Different models of drug 
administration have their own requirements for effective therapy. In 
intravesical instillation, long residence time in the bladder and good drug 
penetration through the urothelium layer are desired. Intravenous injection 
requires long circulation time and low recognition by MPS in the blood system 
as well as the ability to selectively accumulate at tumor sites for reduction of 
systemic toxicity. 
In the first part of the thesis, amine-functionalized polyacrylamide nanogel 
(PAm-NH2) loaded with DTX was evaluated as a mucoadhesive and sustained 
IDDsystem for potential bladder cancer therapy. The use of hydrophobic drugs 
for intravesical chemotherapy is challenging due to the low water-solubility of 
such drugs. To address this problem, the incorporation of DTX (as a model 
hydrophobic drug) into hydrophilic PAm-NH2 nanogels was attempted. DTX 
loading was achieved with high efficiency (>90%) and resulted in increased 
solubility of DTX (>200 folds). The DTX-loaded nanogels released DTX in a 
sustained manner (up to 75%) from the nanogels over 9 days in artificial urine, 
and exhibited similar killing efficiency as free DTX on either UMUC3 or T24 




a critical factor for IDD application, was confirmed by analyzing the ex vivo 
attachment of the PAm-NH2 nanogels on the luminal surface of porcine 
urinary bladder. The nanogels were also taken in by bladder cancer cells in a 
concentration-dependent manner. These results indicate that PAm-NH2 
nanogels can be a promising IDD system for hydrophobic drugs.  
In the second part of the thesis, hollow-structured CM nanocapsules for dual 
drug loading were developed. Dox and peptide-modified CDDP (Pt-ALy) can 
be loaded into the CM nanocapsules with relatively high efficiencies and 
capacities, due to the hollow core and electrostatic interactions with the shell 
of the nanocapsules. The in vitro killing efficacy of the dual drug-loaded 
nanocapsules (CM-Dox-PtALy) against UMUC3 cells after 4 h- and 72 h-
treatment is much higher (with 5-16 times lower IC50) than either Dox- or Pt-
ALy-loaded nanocapsules. The results indicate that Dox and Pt-ALy act in a 
synergistic manner against the UMUC3 cells. Due to the electrostatic 
interactions between the chitosan chains on the surface of the CM 
nanocapsules and the urothelium, these nanocapsules showed strong 
mucoadhesivity on the luminal surface of the bladder without causing obvious 
disruption of the urothelium. 
The work carried out in the first two parts of the thesis focused on IDD 
systems for NMIBC therapy. Mucoadhesivity is highly desired for site-
specific IDD systems in order to prolong the dwell time of drug carriers and 
enhance the penetration of drugs into the bladder wall. On the other hand, 




Importantly, drug carriers should allow minimal release of their cargos prior to 
reaching the target sites and be able to evade the body’s immune system. In 
the third part of the thesis, targeting hybrid nanogels for potential intravenous 
cancer therapy were explored. PAm-NH2 nanogels were loaded with Au NPs 
ranging from ~3 to 7 nm and MTX. MTX was used as both a targeting ligand 
and an anti-cancer drug for chemotherapy. The covalent conjugation of MTX 
to the hybrid nanogels prevented burst release, which may reduce the delivery 
efficiency and cause side effects during systemic circulation. The MTX-
functionalized Au-PAm hybrid nanogels (Au-PAm-MTX) at a dosage of 0.5 
mg/ml or above can kill KB cells with high efficacy (from 30% to 80%) and 
suppress recovery of cancer cells. On the other hand, the viability of 
macrophages showed no significant decrease after incubation with Au-PAm-
MTX for 72 h. The significantly lower uptake of Au-PAm-MTX nanogels by 
macrophages compared to that by KB cells has been shown in Section 5.3.7. 
This indicates that the nanogels are likely to evade clearance by macrophage 
in the physiological environment, and their systemic circulation lifetime will 
be prolonged. This targeting anti-cancer effect is attributed to the much higher 
uptake of the Au-PAm-MTX nanogels by KB cells, compared to that by 
macrophages. These hybrid nanogels can potentially provide safe and effective 
cancer chemotherapy via targeted co-delivery of cytotoxic Au NPs and MTX 
to KB cells. 
In summary, this thesis has shown that the appropriate design of soft 




structures and polymers used, the inherent limitations of intravenous and 
intravesical administration of nanomedicine for cancer therapy can be 
overcome. Ex vivo and in vitro test have demonstrated that these tailored soft 
nanoparticles can be potentially used as effective DDSs in the treatment of 
bladder and ovarian cancers. However, further improvements and testing of 
the DDSs presented in this work are needed prior to clinical applications. 
Some recommendations for future work are provided in the next section. 
 
6.2 Recommendations for Future Work 
Based on the achievements described in this thesis, the following related 
investigations are recommended:  
6.2.1  Combination of siRNA and Chemotherapeutic Drugs in CM 
Nanocapsules for Bladder Cancer Therapy 
The CM nanocapsules discussed in Chapter 4 exhibit the ability to incorporate 
two chemotherapeutic drugs in one formulation. However, chemotherapy is 
not always the primary choice for patients due to the toxic nature of 
chemotherapeutic agents. Gene therapy based on RNA interference (RNAi) is 
a possible solution because RNAi is a naturally occurring downregulation of 
specific genes, which are associated with cancer progression. Small interfering 
RNA (siRNA) is one of the most common forms used to silence these cancer-
specific genes (Elbashir et al., 2001, Ku et al., 2014) and its combined 




for cancer therapy (Yu et al., 2012, Zhao et al., 2015). Recently, a study on 
particle-mediated siRNA-delivery to bladder cancers has been reported 
(Martin et al., 2014). Generally, nanoparticles for siRNA delivery often 
involve cationic moieties, which can easily interact with the negatively 
charged siRNA. CM nanocapsules, with their cationic surface, may serve as 
suitable siRNA carriers. Thus, a combination of siRNA with Dox or Pt-ALy in 
CM nanocapsules for treatment of bladder cancers should be investigated. 
6.2.2  Conjugation of Targeting Peptide on Soft Nanoparticles for 
Bladder Cancer Therapy 
Targeted therapies for urothelial cell carcinoma are expected to become 
increasingly important in the next decade (Dovedi and Davies, 2009). As such, 
the development of soft nanoparticles conjugated with agents that target 
growth factor receptors would be very attractive for bladder cancer treatment. 
The candidates for the design of targeting peptides for bladder tumor cells are 
fibroblast growth receptor 3 (FGFR3), epidermal growth factor receptor 
(EGFR) and cluster of differentiation 47 (CD47). Overexpression and/or 
derangements of these surface receptor proteins have been studied in bladder 
cancers (Chao et al., 2011, Messing, 1990, Willingham et al., 2012, Xia and 
Low, 2010). At present, the use of CD47 in bladder cancer detection and 
diagnostic has been investigated by a group in Stanford (Pan et al., 2014). 
Therefore, there is good rationale for investigating the use of FGFR3, EGFR 





6.2.3  In Vivo Evaluation of Anti-cancer Efficacy of the DDSs 
The investigations carried out in this research work are based on in vitro tests. 
Before DDSs are considered for clinical use, their anti-cancer efficacy should 
be evaluated in vivo. For example, the penetration of DTX into the bladder 
tissue, survival rate of the tumor-bearing mice and the change in tumor size 
should be investigated after intravesical instillation with DTX-PAm-NH2 
nanogels. As shown in Chapter 5, targeting hybrid nanogels (Au-PAm-MTX) 
are potentially promising as an intravenous DDS due to their targeting and 
macrophage-evasion property. Thus, a KB-bearing mouse model should be 
used to investigate the biodistribution of these nanogels after intravenous 
administration and the tumor inhibition effect. The accumulation of the Au-
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